|
MX359371B
(es)
|
2001-11-13 |
2018-09-25 |
Univ Pennsylvania |
Un metodo para detectar y/o identificar secuencias del virus adeno-asociado y aislamiento de secuencias novedosas identificadas de ese modo.
|
|
PT1453547T
(pt)
|
2001-12-17 |
2016-12-28 |
Univ Pennsylvania |
Sequências do vírus adeno-associado (aav) do serotipo 8, vetores contendo as mesmas, e utilizações destas
|
|
US9441244B2
(en)
|
2003-06-30 |
2016-09-13 |
The Regents Of The University Of California |
Mutant adeno-associated virus virions and methods of use thereof
|
|
US9233131B2
(en)
|
2003-06-30 |
2016-01-12 |
The Regents Of The University Of California |
Mutant adeno-associated virus virions and methods of use thereof
|
|
EP2345731B1
(en)
*
|
2003-09-30 |
2015-10-21 |
The Trustees of the University of Pennsylvania |
Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof
|
|
ES2361000T3
(es)
|
2004-04-28 |
2011-06-13 |
The Trustees Of The University Of Pennsylvania |
Suministro secuencial de moléculas inmunogénicas mediante administraciones de un adenovirus y de un virus adeno-asociado.
|
|
CA2563500C
(en)
|
2004-04-28 |
2016-06-28 |
The Trustees Of The University Of Pennsylvania |
Immunization regimen with e4-deleted adenovirus prime and e1-deleted adenovirus boost
|
|
ES2525067T3
(es)
*
|
2005-04-07 |
2014-12-17 |
The Trustees Of The University Of Pennsylvania |
Método de incremento de la función de un vector de AAV
|
|
US7588772B2
(en)
|
2006-03-30 |
2009-09-15 |
Board Of Trustees Of The Leland Stamford Junior University |
AAV capsid library and AAV capsid proteins
|
|
AU2007234698B2
(en)
|
2006-04-07 |
2013-08-01 |
The Board Of Regents Of The University Of Texas System |
Methods and compositions related to adenoassociated virus-phage particles
|
|
WO2008027084A2
(en)
*
|
2006-04-28 |
2008-03-06 |
The Trustees Of The University Of Pennsylvania |
Modified aav vectors having reduced capsid immunogenicity and use thereof
|
|
EP2018421B1
(en)
|
2006-04-28 |
2012-12-19 |
The Trustees of the University of Pennsylvania |
Scalable production method for aav
|
|
US9725485B2
(en)
|
2012-05-15 |
2017-08-08 |
University Of Florida Research Foundation, Inc. |
AAV vectors with high transduction efficiency and uses thereof for gene therapy
|
|
ES2714007T3
(es)
|
2007-04-09 |
2019-05-24 |
Univ Florida |
Composiciones de vectores rAAV que tienen proteínas de la cápside modificadas en tirosina y métodos para su uso
|
|
EP2019143A1
(en)
*
|
2007-07-23 |
2009-01-28 |
Genethon |
CNS gene delivery using peripheral administration of AAV vectors
|
|
EP2058401A1
(en)
|
2007-10-05 |
2009-05-13 |
Genethon |
Widespread gene delivery to motor neurons using peripheral injection of AAV vectors
|
|
WO2009108274A2
(en)
*
|
2008-02-26 |
2009-09-03 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for adeno-associated virus (aav) with hi loop mutations
|
|
WO2009137006A2
(en)
|
2008-04-30 |
2009-11-12 |
The University Of North Carolina At Chapel Hill |
Directed evolution and in vivo panning of virus vectors
|
|
US9217155B2
(en)
|
2008-05-28 |
2015-12-22 |
University Of Massachusetts |
Isolation of novel AAV'S and uses thereof
|
|
US11219696B2
(en)
|
2008-12-19 |
2022-01-11 |
Nationwide Children's Hospital |
Delivery of polynucleotides using recombinant AAV9
|
|
WO2010093784A2
(en)
|
2009-02-11 |
2010-08-19 |
The University Of North Carolina At Chapel Hill |
Modified virus vectors and methods of making and using the same
|
|
EP2425000B1
(en)
*
|
2009-04-30 |
2019-02-20 |
The Trustees Of The University Of Pennsylvania |
Compositions for targeting conducting airway cells comprising adeno-associated virus constructs
|
|
US8734809B2
(en)
|
2009-05-28 |
2014-05-27 |
University Of Massachusetts |
AAV's and uses thereof
|
|
WO2010141706A1
(en)
*
|
2009-06-03 |
2010-12-09 |
Cedars-Sinai Medical Center |
Effective vector platform for gene transfer and gene therapy
|
|
US20120244127A1
(en)
|
2009-10-01 |
2012-09-27 |
The Trustees Of The University Of Pennsylvania |
AAV Vectors Expressing SEC10 for Treating Kidney Damage
|
|
WO2011126808A2
(en)
|
2010-03-29 |
2011-10-13 |
The Trustees Of The University Of Pennsylvania |
Pharmacologically induced transgene ablation system
|
|
US9315825B2
(en)
|
2010-03-29 |
2016-04-19 |
The Trustees Of The University Of Pennsylvania |
Pharmacologically induced transgene ablation system
|
|
EP2561073B1
(en)
|
2010-04-23 |
2016-08-24 |
University of Massachusetts |
Cns targeting aav vectors and methods of use thereof
|
|
US9546369B2
(en)
|
2010-04-23 |
2017-01-17 |
University Of Massachusetts |
Multicistronic expression constructs
|
|
EP3444346B1
(en)
|
2010-04-23 |
2022-07-27 |
University of Massachusetts |
Aav-based treatment of cholesterol-related disorders
|
|
US8663624B2
(en)
|
2010-10-06 |
2014-03-04 |
The Regents Of The University Of California |
Adeno-associated virus virions with variant capsid and methods of use thereof
|
|
WO2012057363A1
(ja)
|
2010-10-27 |
2012-05-03 |
学校法人自治医科大学 |
神経系細胞への遺伝子導入のためのアデノ随伴ウイルスビリオン
|
|
WO2012109570A1
(en)
*
|
2011-02-10 |
2012-08-16 |
The University Of North Carolina At Chapel Hill |
Viral vectors with modified transduction profiles and methods of making and using the same
|
|
TR201908020T4
(tr)
|
2011-02-17 |
2019-06-21 |
Univ Pennsylvania |
Doku özgüllüğünü değiştirmek ve aav9-aracılı gen transferini geliştirmek için bileşimler ve yöntemler.
|
|
WO2012145572A1
(en)
|
2011-04-20 |
2012-10-26 |
The Trustees Of The University Of Pennsylvania |
Regimens and compositions for aav-mediated passive immunization of airborne pathogens
|
|
EP3318635A1
(en)
|
2011-04-21 |
2018-05-09 |
University of Massachusetts |
Raav-based compositions and methods for treating alpha-1 anti-trypsin deficiencies
|
|
CN105755044A
(zh)
|
2011-04-22 |
2016-07-13 |
加利福尼亚大学董事会 |
具有变异衣壳的腺相关病毒病毒体及其使用方法
|
|
US20130039888A1
(en)
*
|
2011-06-08 |
2013-02-14 |
Nationwide Children's Hospital Inc. |
Products and methods for delivery of polynucleotides by adeno-associated virus for lysosomal storage disorders
|
|
ES2857773T5
(es)
*
|
2011-08-24 |
2024-06-04 |
Univ Leland Stanford Junior |
Nuevas proteínas de la cápside de AAV para la transferencia de ácidos nucleicos
|
|
WO2013052915A2
(en)
|
2011-10-05 |
2013-04-11 |
Genelux Corporation |
Method for detecting replication or colonization of a biological therapeutic
|
|
US9226936B2
(en)
|
2011-10-28 |
2016-01-05 |
The Wistar of Anatomy and Biology |
Methods and compositions for enhancing the therapeutic effect of anti-tumor T cells
|
|
US10238755B2
(en)
|
2011-11-30 |
2019-03-26 |
The Wistar Institute Of Anatomy And Biology |
Methods and compositions for regulation of cell aging, carcinogenesis and reprogramming
|
|
EP2601968A1
(en)
*
|
2011-12-06 |
2013-06-12 |
Deutsches Krebsforschungszentrum |
HPV derived polynucleic acids for therapy
|
|
WO2013103896A1
(en)
*
|
2012-01-06 |
2013-07-11 |
Mayo Foundation For Medical Education And Research |
Treating cardiovascular or renal diseases
|
|
US20140087362A1
(en)
|
2012-03-16 |
2014-03-27 |
Aladar A. Szalay |
Methods for assessing effectiveness and monitoring oncolytic virus treatment
|
|
WO2013158265A1
(en)
|
2012-04-20 |
2013-10-24 |
Genelux Corporation |
Imaging methods for oncolytic virus therapy
|
|
WO2013170078A1
(en)
*
|
2012-05-09 |
2013-11-14 |
Oregon Health & Science University |
Adeno associated virus plasmids and vectors
|
|
US10294281B2
(en)
|
2012-05-15 |
2019-05-21 |
University Of Florida Research Foundation, Incorporated |
High-transduction-efficiency rAAV vectors, compositions, and methods of use
|
|
US12358954B2
(en)
|
2012-05-15 |
2025-07-15 |
University Of Florida Research Foundation, Incorporated |
Capsid-modified rAAV vector compositions and methods therefor
|
|
EP2872183B1
(en)
|
2012-07-11 |
2018-09-26 |
The Trustees Of The University Of Pennsylvania |
Aav-mediated gene therapy for rpgr x-linked retinal degeneration
|
|
AU2013296425B2
(en)
|
2012-08-01 |
2018-06-07 |
Nationwide Children's Hospital |
Intrathecal delivery of recombinant adeno-associated virus 9
|
|
EP2692868A1
(en)
|
2012-08-02 |
2014-02-05 |
Universitat Autònoma De Barcelona |
Adeno-associated viral (AAV) vectors useful for transducing adipose tissue
|
|
EP2900686B1
(en)
*
|
2012-09-28 |
2020-06-10 |
The University of North Carolina At Chapel Hill |
Aav vectors targeted to oligodendrocytes
|
|
US20140140959A1
(en)
|
2012-10-05 |
2014-05-22 |
Aladar A. Szalay |
Energy Absorbing-Based Diagnostic and Therapeutic Methods Employing Nucleic Acid Molecules Encoding Chromophore-Producing Enzymes
|
|
EP2749569A1
(en)
|
2012-12-28 |
2014-07-02 |
Annibale Alessandro Puca |
Variant of BPIFB4 protein
|
|
US8957044B2
(en)
|
2013-03-01 |
2015-02-17 |
Wake Forest University Health Sciences |
Systemic gene replacement therapy for treatment of X-linked myotubular myopathy (XLMTM)
|
|
CA2905952A1
(en)
*
|
2013-03-13 |
2014-10-02 |
The Children's Hospital Of Philadelphia |
Adeno-associated virus vectors and methods of use thereof
|
|
WO2014159247A1
(en)
|
2013-03-14 |
2014-10-02 |
University Of Florida Research Foundation, Inc. |
Di-amino acid repeat-containing proteins associated with als
|
|
AU2014235096B2
(en)
|
2013-03-15 |
2020-03-19 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treating MPSI
|
|
ES2926774T3
(es)
*
|
2013-03-15 |
2022-10-28 |
Univ North Carolina Chapel Hill |
Métodos y composiciones para vectores AAV de doble unión de glicano
|
|
WO2015012924A2
(en)
|
2013-04-29 |
2015-01-29 |
The Trustees Of The University Of Pennsylvania |
Tissue preferential codon modified expression cassettes, vectors containing same, and use thereof
|
|
EP3003391B1
(en)
*
|
2013-05-31 |
2021-09-22 |
The Regents of The University of California |
Adeno-associated virus variants and methods of use thereof
|
|
ES2739288T3
(es)
|
2013-09-13 |
2020-01-30 |
California Inst Of Techn |
Recuperación selectiva
|
|
WO2015048534A1
(en)
|
2013-09-26 |
2015-04-02 |
University Of Florida Research Foundation, Inc. |
Synthetic combinatorial aav capsid library for targeted gene therapy
|
|
CN106029107A
(zh)
*
|
2013-10-07 |
2016-10-12 |
基罗米克有限责任公司 |
使用疾病特异性启动子治疗心血管疾病的组合物和方法
|
|
CN106232618A
(zh)
*
|
2013-10-11 |
2016-12-14 |
马萨诸塞眼科耳科诊所 |
预测祖先病毒序列的方法及其用途
|
|
US10238700B2
(en)
|
2014-01-02 |
2019-03-26 |
Genelux Corporation |
Oncolytic virus adjunct therapy with agents that increase virus infectivity
|
|
GB201403684D0
(en)
|
2014-03-03 |
2014-04-16 |
King S College London |
Vector
|
|
US10072251B2
(en)
|
2014-02-19 |
2018-09-11 |
University Of Massachusetts |
Recombinant AAVS having useful transcytosis properties
|
|
SMT202000531T1
(it)
|
2014-03-09 |
2020-11-10 |
Univ Pennsylvania |
Composizioni utili in trattamento di deficit di ornitina transcarbamilasi(otc)
|
|
CA2942289C
(en)
|
2014-03-10 |
2024-05-21 |
Uniqure Ip B.V. |
Further improved aav vectors produced in insect cells
|
|
EP3800191B1
(en)
|
2014-03-17 |
2025-08-20 |
Adverum Biotechnologies, Inc. |
Compositions and methods for enhanced gene expression in cone cells
|
|
CA2942515C
(en)
|
2014-03-18 |
2025-12-09 |
University Of Massachusetts |
Raav-based compositions and methods for treating amyotrophic lateral sclerosis
|
|
EP2933335A1
(en)
|
2014-04-18 |
2015-10-21 |
Genethon |
A method of treating peripheral neuropathies and motor neuron diseases
|
|
WO2015164786A1
(en)
|
2014-04-25 |
2015-10-29 |
University Of Massachusetts |
Recombinant aav vectors useful for reducing immunity against transgene products
|
|
EP3134431B1
(en)
|
2014-04-25 |
2021-04-07 |
The Trustees Of The University Of Pennsylvania |
Ldlr variants and their use in compositions for reducing cholesterol levels
|
|
WO2015164723A1
(en)
|
2014-04-25 |
2015-10-29 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for treating metastatic breast cancer and other cancers in the brain
|
|
ES2833230T3
(es)
|
2014-05-13 |
2021-06-14 |
Univ Pennsylvania |
Composiciones que comprenden AVV que expresan construcciones y usos de doble anticuerpo del mismo
|
|
WO2015187825A2
(en)
|
2014-06-03 |
2015-12-10 |
University Of Massachusetts |
Compositions and methods for modulating dysferlin expression
|
|
EP3151866B1
(en)
|
2014-06-09 |
2023-03-08 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
|
EP2960336A1
(en)
|
2014-06-27 |
2015-12-30 |
Genethon |
Efficient systemic treatment of dystrophic muscle pathologies
|
|
AU2015320694B2
(en)
|
2014-09-24 |
2021-11-11 |
City Of Hope |
Adeno-associated virus vector variants for high efficiency genome editing and methods thereof
|
|
EP3200830B1
(en)
|
2014-10-03 |
2020-09-09 |
University of Massachusetts |
High efficiency library-identified aav vectors
|
|
US10370432B2
(en)
|
2014-10-03 |
2019-08-06 |
University Of Massachusetts |
Heterologous targeting peptide grafted AAVS
|
|
BR112017007765B1
(pt)
|
2014-10-14 |
2023-10-03 |
Halozyme, Inc |
Composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo
|
|
CN107073051B
(zh)
|
2014-10-21 |
2021-08-24 |
马萨诸塞大学 |
重组aav变体及其用途
|
|
US10907130B2
(en)
*
|
2014-11-05 |
2021-02-02 |
Research Institute At Nationwide Children's Hospital |
Methods and materials for producing recombinant viruses in eukaryotic microalgae
|
|
RU2716991C2
(ru)
|
2014-11-05 |
2020-03-17 |
Вояджер Терапьютикс, Инк. |
Полинуклеотиды aadc для лечения болезни паркинсона
|
|
KR20230145206A
(ko)
|
2014-11-14 |
2023-10-17 |
보이저 테라퓨틱스, 인크. |
조절성 폴리뉴클레오티드
|
|
WO2016077687A1
(en)
|
2014-11-14 |
2016-05-19 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating amyotrophic lateral sclerosis (als)
|
|
EP4344741A3
(en)
|
2014-11-21 |
2024-08-28 |
The University of North Carolina at Chapel Hill |
Aav vectors targeted to the central nervous system
|
|
US11697825B2
(en)
|
2014-12-12 |
2023-07-11 |
Voyager Therapeutics, Inc. |
Compositions and methods for the production of scAAV
|
|
WO2016100575A1
(en)
|
2014-12-16 |
2016-06-23 |
Board Of Regents Of The University Of Nebraska |
Gene therapy for juvenile batten disease
|
|
US11033638B2
(en)
|
2015-01-07 |
2021-06-15 |
Universität Autonoma De Barcelona |
Single-vector gene construct comprising insulin and glucokinase genes
|
|
JP6832280B2
(ja)
|
2015-01-16 |
2021-02-24 |
ユニバーシティ オブ ワシントンＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｗａｓｈｉｎｇｔｏｎ |
新規のマイクロジストロフィンおよび使用の関連する方法
|
|
US20180030096A1
(en)
|
2015-02-03 |
2018-02-01 |
University Of Florida Research Foundation, Inc. |
Recombinant aav1, aav5, and aav6 capsid mutants and uses thereof
|
|
WO2016130600A2
(en)
|
2015-02-09 |
2016-08-18 |
Duke University |
Compositions and methods for epigenome editing
|
|
EP3256170B1
(en)
|
2015-02-13 |
2020-09-23 |
University of Massachusetts |
Compositions and methods for transient delivery of nucleases
|
|
US11021519B2
(en)
|
2015-03-02 |
2021-06-01 |
Adverum Biotechnologies, Inc. |
Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
|
|
KR20240119152A
(ko)
|
2015-03-10 |
2024-08-06 |
더 트러스티스 오브 컬럼비아 유니버시티 인 더 시티 오브 뉴욕 |
재조합 glut1 아데노-관련 바이러스 벡터 작제물 및 glut1 발현을 회복하기 위한 관련된 방법
|
|
JP6836999B2
(ja)
*
|
2015-03-24 |
2021-03-03 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ |
アデノ随伴ウイルス変異体及びその使用方法
|
|
US11046955B2
(en)
|
2015-04-24 |
2021-06-29 |
University Of Massachusetts |
Modified AAV constructs and uses thereof
|
|
EP3288594B1
(en)
|
2015-04-27 |
2022-06-29 |
The Trustees of The University of Pennsylvania |
Dual aav vector system for crispr/cas9 mediated correction of human disease
|
|
EP3291765A4
(en)
|
2015-05-07 |
2019-01-23 |
Massachusetts Eye & Ear Infirmary |
METHOD FOR THE DELIVERY OF AN ACTIVE SUBSTANCE TO THE EYE
|
|
GB201508026D0
(en)
|
2015-05-11 |
2015-06-24 |
Ucl Business Plc |
Capsid
|
|
JP6805174B2
(ja)
*
|
2015-05-12 |
2020-12-23 |
アメリカ合衆国 |
神経成長因子シグナルペプチド及び副甲状腺ホルモンを含むａａｖ分離株及び融合タンパク質
|
|
EA201792500A1
(ru)
|
2015-05-13 |
2018-04-30 |
Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания |
Aav-опосредованная экспрессия антител против гриппа и способы их использования
|
|
US20170067028A1
(en)
*
|
2015-05-15 |
2017-03-09 |
Douglas J. Ballon |
Radiolabeling of adeno associated virus
|
|
US10509045B2
(en)
|
2015-05-29 |
2019-12-17 |
University Of Florida Research Foundation, Incorporated |
Methods for diagnosing Huntington's disease
|
|
US10676735B2
(en)
|
2015-07-22 |
2020-06-09 |
Duke University |
High-throughput screening of regulatory element function with epigenome editing technologies
|
|
CN108603235A
(zh)
|
2015-07-30 |
2018-09-28 |
马萨诸塞眼科耳科诊所 |
祖先病毒序列及其用途
|
|
GB2592821B
(en)
|
2015-07-31 |
2022-01-12 |
Univ Minnesota |
Modified cells and methods of therapy
|
|
WO2017024198A1
(en)
|
2015-08-06 |
2017-02-09 |
The Trustees Of The University Of Pennsylvania |
Glp-1 and use thereof in compositions for treating metabolic diseases
|
|
WO2017035416A2
(en)
|
2015-08-25 |
2017-03-02 |
Duke University |
Compositions and methods of improving specificity in genomic engineering using rna-guided endonucleases
|
|
CA2995733A1
(en)
|
2015-08-31 |
2017-03-09 |
The Trustees Of The University Of Pennsylvania |
Aav-epo for treating companion animals
|
|
CN108291216B
(zh)
|
2015-09-24 |
2022-09-16 |
宾夕法尼亚州大学信托人 |
用于治疗补体介导的疾病的组合物和方法
|
|
ES2865487T3
(es)
|
2015-09-28 |
2021-10-15 |
Univ North Carolina Chapel Hill |
Métodos y composiciones para vectores virales que evaden los anticuerpos
|
|
US11273227B2
(en)
|
2015-10-09 |
2022-03-15 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods useful in treating Stargardt's disease and other ocular disorders
|
|
EP4089175A1
(en)
|
2015-10-13 |
2022-11-16 |
Duke University |
Genome engineering with type i crispr systems in eukaryotic cells
|
|
WO2017066764A2
(en)
|
2015-10-16 |
2017-04-20 |
William Marsh Rice University |
Modification of n-terminal region of capsid proteins for enhanced properties of adeno-associated viruses
|
|
WO2017070516A1
(en)
*
|
2015-10-22 |
2017-04-27 |
University Of Massachusetts |
Prostate-targeting adeno-associated virus serotype vectors
|
|
EP3364997B1
(en)
|
2015-10-22 |
2024-01-17 |
University of Massachusetts |
Aspartoacylase gene therapy in the treatment of canavan disease
|
|
US12188037B2
(en)
|
2015-10-22 |
2025-01-07 |
University Of Florida Research Foundation, Incorporated |
Synthetic combinatorial AAV3 capsid library
|
|
WO2017070491A1
(en)
*
|
2015-10-23 |
2017-04-27 |
Applied Genetic Technologies Corporation |
Ophthalmic formulations
|
|
WO2017075335A1
(en)
|
2015-10-28 |
2017-05-04 |
Voyager Therapeutics, Inc. |
Regulatable expression using adeno-associated virus (aav)
|
|
CN108779167A
(zh)
|
2015-10-28 |
2018-11-09 |
宾夕法尼亚州大学信托人 |
鞘内施用腺伴随病毒载体用于基因治疗
|
|
SG11201802408RA
(en)
|
2015-11-05 |
2018-05-30 |
Bamboo Therapeutics Inc |
Modified friedreich ataxia genes and vectors for gene therapy
|
|
EP3384035A4
(en)
|
2015-12-02 |
2019-08-07 |
Voyager Therapeutics, Inc. |
ASSAYS FOR THE DETECTION OF AAV-NEUTRALIZING ANTIBODIES
|
|
FR3044926B1
(fr)
|
2015-12-09 |
2020-01-31 |
Genethon |
Outils de therapie genique efficaces pour le saut de l'exon 53 de la dystrophine
|
|
US11028372B2
(en)
|
2015-12-11 |
2021-06-08 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for AAVRH10
|
|
AU2016366560A1
(en)
|
2015-12-11 |
2018-06-28 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating familial hypercholesterolemia
|
|
WO2017100674A1
(en)
|
2015-12-11 |
2017-06-15 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aav1
|
|
KR102423442B1
(ko)
*
|
2015-12-11 |
2022-07-20 |
캘리포니아 인스티튜트 오브 테크놀로지 |
아데노-관련 바이러스를 지시하기 위한 타겟팅 펩타이드
|
|
SG10201913266UA
(en)
|
2015-12-11 |
2020-02-27 |
Massachusetts Eye & Ear Infirmary |
Materials and methods for delivering nucleic acids to cochlear and vestibular cells
|
|
EP3387138B1
(en)
|
2015-12-11 |
2022-01-26 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aav9
|
|
ES2934848T3
(es)
|
2015-12-11 |
2023-02-27 |
Univ Pennsylvania |
Método de purificación escalable para AAV8
|
|
JP7061067B2
(ja)
|
2015-12-14 |
2022-04-27 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
クリグラー・ナジャー症候群の処置のための組成物
|
|
MX2018007234A
(es)
*
|
2015-12-14 |
2018-11-09 |
Univ Pennsylvania |
Vectores virales adenoasociados utiles en el tratamiento de atrofia muscular espinal.
|
|
CA3008264A1
(en)
|
2015-12-14 |
2017-06-22 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for ocular disorders
|
|
CA3011939A1
(en)
|
2016-02-02 |
2017-08-10 |
University Of Massachusetts |
Method to enhance the efficiency of systemic aav gene delivery to the central nervous system
|
|
CA3012195A1
(en)
|
2016-02-03 |
2017-08-10 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating mucopolysaccharidosis type i
|
|
EP3411484B1
(en)
|
2016-02-05 |
2023-10-04 |
Emory University |
Injection of single-stranded or self-complementary adeno-associated virus 9 into the cerebrospinal fluid
|
|
CA3012344A1
(en)
|
2016-02-12 |
2017-08-17 |
University Of Massachusetts |
Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
|
|
US10940161B2
(en)
|
2016-04-04 |
2021-03-09 |
University Of Florida Research Foundation, Incorporated |
Manipulation of EIF3 to modulate repeat associated non-ATG (RAN) translation
|
|
US11207426B2
(en)
|
2016-04-05 |
2021-12-28 |
University Of Massachusetts |
Compositions and methods for selective inhibition of grainyhead-like protein expression
|
|
US11446398B2
(en)
|
2016-04-11 |
2022-09-20 |
Obsidian Therapeutics, Inc. |
Regulated biocircuit systems
|
|
US20190127713A1
(en)
|
2016-04-13 |
2019-05-02 |
Duke University |
Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
|
|
SG11201808426XA
(en)
|
2016-04-15 |
2018-10-30 |
Univ Pennsylvania |
Compositions for treatment of wet age-related macular degeneration
|
|
WO2017181152A2
(en)
|
2016-04-15 |
2017-10-19 |
Alpine Immune Sciences, Inc. |
Cd80 variant immunomodulatory proteins and uses thereof
|
|
US11413356B2
(en)
|
2016-04-15 |
2022-08-16 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance
|
|
MX2018012537A
(es)
|
2016-04-15 |
2019-02-25 |
Univ Pennsylvania |
Terapia de genes para tratar hemofilia a.
|
|
SG10201912761UA
(en)
|
2016-04-15 |
2020-02-27 |
The Trustees Of The Univ Of Pennsyvania |
Gene therapy for treating mucopolysaccharidosis type ii
|
|
MX2018012472A
(es)
|
2016-04-15 |
2019-08-12 |
Alpine Immune Sciences Inc |
Proteinas inmunomoduladoras variantes de ligando icos y sus usos.
|
|
SG11201808812RA
(en)
*
|
2016-04-15 |
2018-11-29 |
Univ Pennsylvania |
Novel aav8 mutant capsids and compositions containing same
|
|
US11401527B2
(en)
|
2016-04-17 |
2022-08-02 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods useful for prophylaxis of organophosphates
|
|
US11299751B2
(en)
|
2016-04-29 |
2022-04-12 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
|
EP3448874A4
(en)
|
2016-04-29 |
2020-04-22 |
Voyager Therapeutics, Inc. |
COMPOSITIONS FOR TREATING A DISEASE
|
|
AU2017261249B2
(en)
*
|
2016-05-03 |
2021-05-06 |
Children's Medical Research Institute |
Adeno-associated virus polynucleotides, polypeptides and virions
|
|
US11364308B2
(en)
|
2016-05-13 |
2022-06-21 |
4D Molecular Therapeutics Inc. |
Adeno-associated virus variant capsids and methods of use thereof
|
|
KR102427379B1
(ko)
|
2016-05-18 |
2022-08-02 |
보이저 테라퓨틱스, 인크. |
헌팅톤 질환을 치료하기 위한 조성물 및 방법
|
|
KR20240056729A
(ko)
|
2016-05-18 |
2024-04-30 |
보이저 테라퓨틱스, 인크. |
조절성 폴리뉴클레오티드
|
|
CN109415730A
(zh)
|
2016-06-13 |
2019-03-01 |
北卡罗来纳大学教堂山分校 |
优化的cln1基因和表达盒以及它们的应用
|
|
US11882815B2
(en)
|
2016-06-15 |
2024-01-30 |
University Of Massachusetts |
Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
|
|
CA2971303C
(en)
|
2016-06-21 |
2026-03-03 |
Bamboo Therapeutics, Inc. |
Optimized mini-dystrophin genes and expression cassettes and their use
|
|
WO2018009814A1
(en)
|
2016-07-08 |
2018-01-11 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for treatment of disorders and diseases involving rdh12
|
|
JP7490211B2
(ja)
|
2016-07-19 |
2024-05-27 |
デューク ユニバーシティ |
Ｃｐｆ１に基づくゲノム編集の治療適用
|
|
WO2018022511A1
(en)
|
2016-07-25 |
2018-02-01 |
The Trustees Of The University Of Pennsylvania |
Compositions comprising a lecithin cholesterol acyltransferase variant and uses thereof
|
|
IL305149A
(en)
*
|
2016-07-26 |
2023-10-01 |
Biomarin Pharm Inc |
Novel adeno-associated virus capsid proteins
|
|
WO2018022946A1
(en)
|
2016-07-28 |
2018-02-01 |
Alpine Immune Sciences, Inc. |
Cd155 variant immunomodulatory proteins and uses thereof
|
|
WO2018022945A1
(en)
|
2016-07-28 |
2018-02-01 |
Alpine Immune Sciences, Inc. |
Cd112 variant immunomodulatory proteins and uses thereof
|
|
US11471488B2
(en)
|
2016-07-28 |
2022-10-18 |
Alpine Immune Sciences, Inc. |
CD155 variant immunomodulatory proteins and uses thereof
|
|
AU2017302013B2
(en)
|
2016-07-29 |
2022-05-26 |
The Regents Of The University Of California |
Adeno-associated virus virions with variant capsid and methods of use thereof
|
|
IL315358A
(en)
|
2016-08-18 |
2024-11-01 |
Univ California |
CRISPR-CAS genome engineering using a modular AAV delivery system
|
|
WO2018044933A1
(en)
|
2016-08-30 |
2018-03-08 |
The Regents Of The University Of California |
Methods for biomedical targeting and delivery and devices and systems for practicing the same
|
|
US10457940B2
(en)
|
2016-09-22 |
2019-10-29 |
University Of Massachusetts |
AAV treatment of Huntington's disease
|
|
AU2017341849B2
(en)
|
2016-10-13 |
2024-03-21 |
University Of Massachusetts |
AAV capsid designs
|
|
CN110520530A
(zh)
|
2016-10-18 |
2019-11-29 |
明尼苏达大学董事会 |
肿瘤浸润性淋巴细胞和治疗方法
|
|
CA3040179A1
(en)
|
2016-10-19 |
2018-04-26 |
Adverum Biotechnologies, Inc. |
Modified aav capsids and uses thereof
|
|
WO2018075978A1
(en)
|
2016-10-20 |
2018-04-26 |
Alpine Immune Sciences, Inc. |
Secretable variant immunomodulatory proteins and engineered cell therapy
|
|
EP3535396A1
(en)
|
2016-11-01 |
2019-09-11 |
Novartis AG |
Methods and compositions for enhancing gene editing
|
|
US20190328846A1
(en)
|
2016-12-01 |
2019-10-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Pharmaceutical compositions for the treatment of retinal degenerative diseases
|
|
BR112019013245A2
(pt)
|
2016-12-30 |
2020-02-11 |
The Trustees Of The University Of Pennsylvania |
Terapia gênica para tratamento da doença de wilson
|
|
KR102738752B1
(ko)
|
2016-12-30 |
2024-12-06 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
페닐케톤뇨증을 치료하기 위한 유전자 치료
|
|
WO2018134168A1
(en)
|
2017-01-17 |
2018-07-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of expressing a polynucleotide of interest in the cone photoreceptors
|
|
KR20250022877A
(ko)
|
2017-01-31 |
2025-02-17 |
리젠엑스바이오 인크. |
완전히-인간 글리코실화된 인간 알파-l-이두로니다아제(idua)를 이용한 뮤코다당증 1형의 치료
|
|
WO2018144709A2
(en)
|
2017-02-01 |
2018-08-09 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating citrullenemia
|
|
CN110546265A
(zh)
|
2017-02-09 |
2019-12-06 |
因达普塔治疗公司 |
工程化自然杀伤(nk)细胞及其组合物和方法
|
|
JP2020510648A
(ja)
|
2017-02-20 |
2020-04-09 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
家族性高コレステロール血症を処置するための遺伝子治療
|
|
EP3585883A4
(en)
|
2017-02-21 |
2021-04-14 |
University of Florida Research Foundation, Incorporated |
MODIFIED AAV CAPSID PROTEINS AND USES THEREOF
|
|
EP3655533A1
(en)
|
2017-02-24 |
2020-05-27 |
Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin |
Method for re-expression of different hypermethylated genes involved in fibrosis, like hypermethylated rasal,1 and use thereof in treatment of fibrosis as well as kit of parts for re-expression of hypermethylated genes including rasal1 in a subject
|
|
PT3589730T
(pt)
*
|
2017-02-28 |
2024-02-28 |
Univ Pennsylvania |
Vetor de vírus adenoassociado (aav) de clado f e suas utilizações
|
|
JOP20190200A1
(ar)
|
2017-02-28 |
2019-08-27 |
Univ Pennsylvania |
تركيبات نافعة في معالجة ضمور العضل النخاعي
|
|
UY37620A
(es)
*
|
2017-02-28 |
2018-08-31 |
Univ Pennsylvania |
Vacunas contra la gripe mediadas por aav novedosas
|
|
RU2019130004A
(ru)
|
2017-03-01 |
2021-04-01 |
Зе Трастис Оф Зе Юниверсити Оф Пеннсильвания |
Генная терапия при глазных заболеваниях
|
|
WO2018158397A1
(en)
|
2017-03-02 |
2018-09-07 |
Genethon |
Method for removing anti-aav antibodies from a blood-derived composition
|
|
CA3055200A1
(en)
|
2017-03-03 |
2018-09-07 |
Obsidian Therapeutics, Inc. |
Compositions and methods for immunotherapy
|
|
KR102746901B1
(ko)
|
2017-03-03 |
2024-12-26 |
옵시디안 테라퓨틱스, 인크. |
Cd19 조성물 및 면역요법을 위한 방법
|
|
KR20190141146A
(ko)
|
2017-03-16 |
2019-12-23 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
Pd-l2 변이체 면역조절 단백질 및 그의 용도
|
|
EP3596116B1
(en)
|
2017-03-16 |
2023-09-06 |
Alpine Immune Sciences, Inc. |
Pd-l1 variant immunomodulatory proteins and uses thereof
|
|
SG11201907769XA
(en)
|
2017-03-16 |
2019-09-27 |
Alpine Immune Sciences Inc |
Cd80 variant immunomodulatory proteins and uses thereof
|
|
IL312457A
(en)
|
2017-03-24 |
2024-06-01 |
Lankenau Inst Medical Res |
Methods and compositions for inducible extracellular membrane trapping of monoclonal immunoglobulins secreted by hybridomas
|
|
CN118813559A
(zh)
|
2017-03-31 |
2024-10-22 |
北京三诺佳邑生物技术有限责任公司 |
shRNA表达框、携带其的多核苷酸序列及其应用
|
|
EP3610016A1
(en)
|
2017-04-10 |
2020-02-19 |
Genethon |
Antisense targeting dynamin 2 and use for the treatment of centronuclear myopathies and neuropathies
|
|
KR20190139951A
(ko)
|
2017-04-14 |
2019-12-18 |
리젠엑스바이오 인크. |
인간 뉴런 또는 신경교 세포에 의해 생성된 재조합 인간 이두로네이트-2 설파타제(ids)를 이용한 뮤코다당증 ii형의 치료
|
|
WO2018195110A1
(en)
*
|
2017-04-17 |
2018-10-25 |
University Of Florida Research Foundation, Incorporated |
Regolation of ran translation by pkr and eif2a-p pathways
|
|
WO2018200542A1
(en)
|
2017-04-24 |
2018-11-01 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for ocular disorders
|
|
JP2020518258A
(ja)
|
2017-05-05 |
2020-06-25 |
ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
筋萎縮性側索硬化症（ａｌｓ）治療組成物および方法
|
|
JP2020518259A
(ja)
|
2017-05-05 |
2020-06-25 |
ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
ハンチントン病治療組成物および方法
|
|
US11859179B2
(en)
|
2017-05-09 |
2024-01-02 |
University Of Massachusetts |
Methods of treating amyotrophic lateral sclerosis (ALS)
|
|
CA3061968A1
(en)
|
2017-05-10 |
2018-11-15 |
Massachusetts Eye And Ear Infirmary |
Methods and compositions for modifying assembly-activating protein (aap)-dependence of viruses
|
|
IL316926A
(en)
|
2017-05-11 |
2025-01-01 |
Univ Pennsylvania |
Gene therapy for neuronal ceroid lipofuscinosis
|
|
IL270882B2
(en)
|
2017-05-24 |
2024-02-01 |
Univ Barcelona Autonoma |
Viral expression vectors containing the coding sequence for FIBROBLAST GROWTH FACTOR 21 (FGF21
|
|
EP3630986B1
(en)
|
2017-05-31 |
2026-03-25 |
The Trustees of The University of Pennsylvania |
Gene therapy for treating peroxisomal disorders
|
|
JP7766393B2
(ja)
|
2017-06-14 |
2025-11-10 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
眼疾患のための遺伝子療法
|
|
JOP20190269A1
(ar)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
بولي نوكليوتيدات aadc لعلاج مرض باركنسون
|
|
CA3053154A1
(en)
|
2017-06-30 |
2019-01-03 |
The Regents Of The University Of California |
Adeno-associated virus virions with variant capsids and methods of use thereof
|
|
EP3645021A4
(en)
|
2017-06-30 |
2021-04-21 |
Intima Bioscience, Inc. |
ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
|
|
CA3068328A1
(en)
|
2017-07-06 |
2019-01-10 |
The Trustees Of The University Of Pennsylvania |
Aav9-mediated gene therapy for treating mucopolysaccharidosis type i
|
|
ES2986113T3
(es)
|
2017-07-07 |
2024-11-08 |
Genethon |
Nuevos polinucleótidos que codifican una proteína FKRP humana
|
|
CA3070087A1
(en)
|
2017-07-17 |
2019-01-24 |
Voyager Therapeutics, Inc. |
Trajectory array guide system
|
|
BR112020001060A2
(pt)
|
2017-07-27 |
2020-07-14 |
Novartis Ag |
variantes de trem2 resistentes a shedase
|
|
EP3808849A1
(en)
|
2017-08-03 |
2021-04-21 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
JP2020534788A
(ja)
|
2017-08-28 |
2020-12-03 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
アデノ随伴ウイルスカプシド変異体及びその使用方法
|
|
RU2770922C2
(ru)
|
2017-09-20 |
2022-04-25 |
4Д Молекьюлар Терапьютикс Инк. |
Капсиды вариантов аденоассоциированных вирусов и методы их применения
|
|
CN111448321A
(zh)
|
2017-09-22 |
2020-07-24 |
马萨诸塞大学 |
Sod1双表达载体及其用途
|
|
KR102883778B1
(ko)
|
2017-09-22 |
2025-11-12 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
Ii형 점액다당류증의 치료를 위한 유전자 요법
|
|
EP3688020A4
(en)
|
2017-09-25 |
2021-07-14 |
University of Florida Research Foundation, Incorporated |
IMMUNOASSAYS FOR DETECTION OF RAN PROTEINS
|
|
AU2018342105B2
(en)
|
2017-09-26 |
2023-11-16 |
University Of Florida Research Foundation, Incorporated |
Use of metformin and analogs thereof to reduce ran protein levels in the treatment of neurological disorders
|
|
AU2018338728B2
(en)
|
2017-09-29 |
2025-01-02 |
Centre National De La Recherche Scientifique (Cnrs) |
Rescue of central and peripheral neurological phenotype of Friedreich's Ataxia by intravenous delivery
|
|
TW202413649A
(zh)
|
2017-10-16 |
2024-04-01 |
美商航海家醫療公司 |
肌萎縮性脊髓側索硬化症(als)之治療
|
|
EP3697908A1
(en)
|
2017-10-16 |
2020-08-26 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis (als)
|
|
MX2020003888A
(es)
|
2017-10-18 |
2020-11-06 |
Regenxbio Inc |
Anticuerpos terapeuticos postraduccionalmente modificados completamente humanos.
|
|
BR112020007542A2
(pt)
|
2017-10-18 |
2020-12-01 |
Alpine Immune Sciences, Inc. |
proteínas imunomoduladoras ligantes de icos variantes e composições e métodos relacionados
|
|
AU2018350990A1
(en)
|
2017-10-18 |
2020-05-21 |
Regenxbio Inc. |
Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified VEGF-Trap
|
|
CN111867635A
(zh)
|
2017-10-20 |
2020-10-30 |
法国国家卫生及研究医学协会 |
包括视网膜下递送治疗有效量的重组aav9衍生载体的在对象的视锥细胞光感受器中表达目的多核苷酸的方法
|
|
CN111770999A
(zh)
|
2017-11-27 |
2020-10-13 |
4D分子治疗有限公司 |
腺相关病毒变体衣壳和用于抑制血管生成的应用
|
|
AU2018375164B2
(en)
|
2017-11-30 |
2025-05-15 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for Mucopolysaccharidosis IIIA
|
|
CN111989396A
(zh)
|
2017-11-30 |
2020-11-24 |
宾夕法尼亚州大学信托人 |
用于iiib型粘多糖贮积病的基因疗法
|
|
EP3727468A4
(en)
|
2017-12-19 |
2021-09-22 |
Akouos, Inc. |
AAV-MEDIATED THERAPEUTIC ANTIBODIES DELIVERY TO THE INTERNAL EAR
|
|
AU2019205273B2
(en)
|
2018-01-03 |
2024-04-04 |
Alpine Immune Sciences, Inc. |
Multi-domain immunomodulatory proteins and methods of use thereof
|
|
CA3088323A1
(en)
|
2018-01-17 |
2019-07-25 |
Adrenas Therapeutics, Inc. |
Adeno-associated virus gene therapy for 21-hydroxylase deficiency
|
|
US20190256867A1
(en)
|
2018-02-01 |
2019-08-22 |
Homology Medicines, Inc. |
Adeno-associated virus compositions for restoring pah gene function and methods of use thereof
|
|
US10610606B2
(en)
|
2018-02-01 |
2020-04-07 |
Homology Medicines, Inc. |
Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
|
|
JP7244547B2
(ja)
|
2018-02-19 |
2023-03-22 |
ホモロジー・メディシンズ・インコーポレイテッド |
Ｆ８遺伝子機能を回復させるためのアデノ随伴ウイルス組成物及びその使用の方法
|
|
US12558434B2
(en)
|
2018-02-20 |
2026-02-24 |
The Trustees Of The University Of Pennsylvania |
Compositions for treatment of wet age-related macular degeneration
|
|
EP3768695A4
(en)
*
|
2018-02-27 |
2022-04-06 |
The Trustees of the University of Pennsylvania |
NOVEL ADENO-ASSOCIATED VIRUS (AAV) VECTORS, AAV VECTORS WITH REDUCED CAPSIID DEAMIDATION AND USES THEREOF
|
|
IL276859B2
(en)
*
|
2018-02-27 |
2025-12-01 |
Univ Pennsylvania |
Novel adeno-associated virus (aav) vectors, aav vectors having reduced capsid deamidation and uses therefor
|
|
EP3765624A4
(en)
*
|
2018-03-16 |
2022-05-25 |
Research Institute at Nationwide Children's Hospital |
Increasing tissue specific gene delivery by capsid modification
|
|
EP3774852A1
(en)
|
2018-04-03 |
2021-02-17 |
Stridebio, Inc. |
Antibody-evading virus vectors
|
|
MX2020010465A
(es)
|
2018-04-03 |
2021-01-08 |
|
Vectores de virus para direccionamiento a tejidos oftalmicos.
|
|
AU2019247748A1
(en)
|
2018-04-03 |
2020-10-08 |
Ginkgo Bioworks, Inc. |
Antibody-evading virus vectors
|
|
US12037707B2
(en)
|
2018-04-05 |
2024-07-16 |
Massachusetts Eye And Ear Infirmary |
Methods of making and using combinatorial barcoded nucleic acid libraries having defined variation
|
|
MA51353B1
(fr)
|
2018-04-05 |
2022-09-30 |
Univ Sorbonne |
Sérotype du virus adéno-associé recombinant hybride entre aav9 et aavrh74 possédant un tropisme hépatique réduit
|
|
US12460226B2
(en)
|
2018-04-16 |
2025-11-04 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treating duchenne muscular dystrophy
|
|
CN112312929A
(zh)
|
2018-04-18 |
2021-02-02 |
纽约市哥伦比亚大学理事会 |
用于包括线粒体dna耗竭综合征在内的由不平衡的核苷酸库引起的疾病的基因疗法
|
|
MX2020011386A
(es)
|
2018-04-27 |
2021-01-29 |
Spacecraft Seven Llc |
Terapia genica para la degeneracion del snc.
|
|
CA3098565A1
(en)
|
2018-04-29 |
2019-11-07 |
Claire G. ZHANG |
Scalable clarification process for recombinant aav production
|
|
WO2019212922A1
(en)
|
2018-04-29 |
2019-11-07 |
Regenxbio Inc. |
Systems and methods of spectrophotometry for the determination of genome content, capsid content and full/empty ratios of adeno-associated virus particles
|
|
AU2019265663B2
(en)
|
2018-05-08 |
2024-06-13 |
Rutgers, The State University Of New Jersey |
AAV-compatible laminin-linker polymerization proteins
|
|
TW202016314A
(zh)
|
2018-05-09 |
2020-05-01 |
美商拜奧馬林製藥公司 |
治療苯丙酮尿症之方法
|
|
CA3100006A1
(en)
|
2018-05-11 |
2019-11-14 |
Massachusetts Eye And Ear Infirmary |
Altering tissue tropism of adeno-associated viruses
|
|
TW202005978A
(zh)
|
2018-05-14 |
2020-02-01 |
美商拜奧馬林製藥公司 |
新穎肝靶向腺相關病毒載體
|
|
EP3813845A4
(en)
|
2018-05-15 |
2022-10-26 |
President And Fellows Of Harvard College |
Viral vectors exhibiting improved gene delivery properties
|
|
WO2019222329A1
(en)
|
2018-05-15 |
2019-11-21 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
KR20210019996A
(ko)
|
2018-05-15 |
2021-02-23 |
보이저 테라퓨틱스, 인크. |
파킨슨병의 치료를 위한 조성물 및 방법
|
|
TWI869346B
(zh)
|
2018-05-30 |
2025-01-11 |
瑞士商諾華公司 |
Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
|
|
EA202000353A1
(ru)
|
2018-06-04 |
2022-01-14 |
Калиди Биотерапьютикс, Инк. |
Основанные на клетках носители для потенциализации вирусной терапии
|
|
US11505782B2
(en)
|
2018-06-04 |
2022-11-22 |
Calidi Biotherapeutics, Inc. |
Cell-based vehicles for potentiation of viral therapy
|
|
WO2019236995A1
(en)
|
2018-06-08 |
2019-12-12 |
University Of Massachusetts |
Antisense oligonucleotides to restore dysferlin protein expression in dysferlinopathy patient cells
|
|
WO2019241315A1
(en)
|
2018-06-12 |
2019-12-19 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
|
WO2019241486A1
(en)
|
2018-06-13 |
2019-12-19 |
Voyager Therapeutics, Inc. |
Engineered 5' untranslated regions (5' utr) for aav production
|
|
US12070702B2
(en)
|
2018-06-14 |
2024-08-27 |
Regenxbio Inc. |
Anion exchange chromatography for recombinant AAV production
|
|
WO2019241758A1
(en)
|
2018-06-15 |
2019-12-19 |
Alpine Immune Sciences, Inc. |
Pd-1 variant immunomodulatory proteins and uses thereof
|
|
GB201811368D0
(en)
|
2018-07-11 |
2018-08-29 |
Ucb Biopharma Sprl |
Antibody
|
|
KR102918544B1
(ko)
|
2018-07-12 |
2026-01-27 |
로켓 파마슈티컬스, 리미티드 |
다논병을 치료하기 위한 유전자 요법 벡터
|
|
EP3823981A4
(en)
|
2018-07-17 |
2022-04-06 |
Neuromyon Inc. |
TREATMENT OF NEUROPATHY WITH DNA CONSTRUCTS EXPRESSING IGF-1 ISOFORMS
|
|
US20210322473A1
(en)
*
|
2018-07-18 |
2021-10-21 |
The General Hospital Corporation |
Modified t cells and methods of their use
|
|
CN112770812A
(zh)
|
2018-07-24 |
2021-05-07 |
沃雅戈治疗公司 |
产生基因治疗制剂的系统和方法
|
|
WO2020028751A2
(en)
|
2018-08-03 |
2020-02-06 |
Voyager Therapeutics, Inc. |
Aav variants with enhanced tropism
|
|
EP3833745A1
(en)
|
2018-08-10 |
2021-06-16 |
REGENXBIO Inc. |
Scalable method for recombinant aav production
|
|
CA3109804A1
(en)
|
2018-08-16 |
2020-02-20 |
The Regents Of The University Of California |
Chemically and photochemically initiated cell membrane blebbing to induce cell vesicle production, modifications thereof, and uses thereof
|
|
US11242528B2
(en)
|
2018-08-28 |
2022-02-08 |
Actym Therapeutics, Inc. |
Engineered immunostimulatory bacterial strains and uses thereof
|
|
JP7450945B2
(ja)
|
2018-08-30 |
2024-03-18 |
テナヤ セラピューティクス， インコーポレイテッド |
ミオカルディンおよびａｓｃｌ１を用いた心細胞リプログラミング
|
|
CN113966399A
(zh)
|
2018-09-26 |
2022-01-21 |
加州理工学院 |
用于靶向基因疗法的腺相关病毒组合物
|
|
EP3856762A1
(en)
|
2018-09-28 |
2021-08-04 |
Voyager Therapeutics, Inc. |
Frataxin expression constructs having engineered promoters and methods of use thereof
|
|
CA3114175A1
(en)
|
2018-10-01 |
2020-04-09 |
The Trustees Of The University Of Pennsylvania |
Beta-galactosidase based aav for treating gm1 gangliosidosis
|
|
JP7289033B2
(ja)
|
2018-10-01 |
2023-06-09 |
徹 宮崎 |
神経変性疾患治療剤
|
|
BR112021006052A2
(pt)
|
2018-10-01 |
2021-09-08 |
Ultragenyx Pharmaceutical Inc. |
Terapia gênica para tratar acidemia propiônica
|
|
CN113166208B
(zh)
|
2018-10-02 |
2024-11-22 |
沃雅戈治疗公司 |
重新定向aav衣壳的嗜性
|
|
WO2020072849A1
(en)
|
2018-10-04 |
2020-04-09 |
Voyager Therapeutics, Inc. |
Methods for measuring the titer and potency of viral vector particles
|
|
WO2020072844A1
(en)
|
2018-10-05 |
2020-04-09 |
Voyager Therapeutics, Inc. |
Engineered nucleic acid constructs encoding aav production proteins
|
|
US20210371470A1
(en)
|
2018-10-12 |
2021-12-02 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
|
CN112912518A
(zh)
|
2018-10-15 |
2021-06-04 |
再生生物股份有限公司 |
用于测量复制缺陷型病毒载体和病毒的感染性的方法
|
|
CN113166781A
(zh)
|
2018-10-15 |
2021-07-23 |
沃雅戈治疗公司 |
在杆状病毒/Sf9系统中大规模生产rAAV的表达载体
|
|
AU2019365100B2
(en)
|
2018-10-22 |
2025-10-09 |
University Of Rochester |
Genome editing by directed non-homologous DNA insertion using a retroviral integrase-Cas9 fusion protein
|
|
US20210386788A1
(en)
|
2018-10-24 |
2021-12-16 |
Obsidian Therapeutics, Inc. |
Er tunable protein regulation
|
|
CA3116192C
(en)
|
2018-11-06 |
2025-09-23 |
Calidi Biotherapeutics (Nevada), Inc. |
IMPROVED SYSTEMS FOR CELL-MEDIATED ONCOLYTIC VIRAL THERAPY
|
|
WO2020101042A1
(en)
|
2018-11-16 |
2020-05-22 |
Astellas Pharma Inc. |
Method for treating muscular dystrophy by targeting utrophin gene
|
|
EP3884041A2
(en)
|
2018-11-21 |
2021-09-29 |
Indapta Therapeutics, Inc. |
Methods for expansion of natural killer (nk) cell subset and related compositions and methods
|
|
CA3120868A1
(en)
|
2018-11-30 |
2020-06-04 |
Alpine Immune Sciences, Inc. |
Cd86 variant immunomodulatory proteins and uses thereof
|
|
CN120860258A
(zh)
*
|
2018-11-30 |
2025-10-31 |
北京诺华制药有限公司 |
Aav病毒载体及其用途
|
|
KR20220022107A
(ko)
|
2018-12-05 |
2022-02-24 |
아베오나 테라퓨틱스 인코퍼레이티드 |
유전자 전달을 위한 재조합 아데노-연관 바이러스 벡터
|
|
US20220089670A1
(en)
|
2018-12-28 |
2022-03-24 |
University Of Rochester |
Gene Therapy for BEST1 Dominant Mutations
|
|
DK3906066T5
(da)
|
2019-01-04 |
2024-08-05 |
Ultragenyx Pharmaceutical Inc |
Geneterapikonstruktioner til behandling af wilsons sygdom
|
|
AU2020208346B2
(en)
|
2019-01-14 |
2026-01-29 |
University Of Rochester |
Targeted nuclear RNA cleavage and polyadenylation with CRISPR-cas
|
|
SG11202107645RA
(en)
|
2019-01-18 |
2021-08-30 |
Voyager Therapeutics Inc |
Methods and systems for producing aav particles
|
|
WO2020160508A1
(en)
|
2019-01-31 |
2020-08-06 |
Oregon Health & Science University |
Methods for using transcription-dependent directed evolution of aav capsids
|
|
BR112021015817A2
(pt)
|
2019-02-22 |
2021-10-13 |
The Trustees Of The University Of Pennsylvania |
Vírus adeno-associado recombinante para tratamento de neurodegeneração com início na idade adulta associado a grn
|
|
US20220154211A1
(en)
|
2019-02-25 |
2022-05-19 |
Novartis Ag |
Compositions and methods to treat bietti crystalline dystrophy
|
|
SG11202108044YA
(en)
|
2019-02-25 |
2021-09-29 |
Novartis Ag |
Compositions and methods to treat bietti crystalline dystrophy
|
|
EP3931337A1
(en)
|
2019-02-26 |
2022-01-05 |
The Trustees of The University of Pennsylvania |
Compositions useful in treatment of krabbe disease
|
|
JP2022524951A
(ja)
|
2019-02-27 |
2022-05-11 |
アクティム・セラピューティクス・インコーポレイテッド |
腫瘍、腫瘍常在免疫細胞および腫瘍微小環境にコロニー形成するよう操作した免疫刺激性細菌
|
|
US12024709B2
(en)
|
2019-02-27 |
2024-07-02 |
Actym Therapeutics, Inc. |
Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
|
|
CN113795279B
(zh)
|
2019-03-04 |
2024-12-31 |
宾夕法尼亚州大学信托人 |
靶向akt通路的神经保护性基因疗法
|
|
AR118465A1
(es)
|
2019-03-21 |
2021-10-06 |
Stridebio Inc |
Vectores de virus adenoasociados recombinantes
|
|
US12466864B2
(en)
|
2019-03-25 |
2025-11-11 |
Genethon |
Production of large-sized quasidystrophins using overlapping AAV vectors
|
|
EP3947700A4
(en)
|
2019-04-01 |
2023-01-04 |
Tenaya Therapeutics, Inc. |
Adeno-associated virus with engineered capsid
|
|
WO2020206098A1
(en)
|
2019-04-03 |
2020-10-08 |
Regenxbio Inc. |
Gene therapy for eye pathologies
|
|
TW202102526A
(zh)
|
2019-04-04 |
2021-01-16 |
美商銳進科斯生物股份有限公司 |
重組腺相關病毒及其用途
|
|
FI3953483T3
(fi)
|
2019-04-11 |
2023-11-30 |
Regenxbio Inc |
Kokoekskluusiokromatografiamenetelmiä rekombinanttien adenoassosioituneiden viruskoostumusten karakterisoimiseksi
|
|
TW202332458A
(zh)
|
2019-04-19 |
2023-08-16 |
美商銳進科斯生物股份有限公司 |
腺相關病毒載體調配物及方法
|
|
WO2020219868A1
(en)
|
2019-04-24 |
2020-10-29 |
Regenxbio Inc. |
Fully-human post-translationally modified antibody therapeutics
|
|
EP3962536A1
(en)
|
2019-04-29 |
2022-03-09 |
Voyager Therapeutics, Inc. |
Systems and methods for producing baculoviral infected insect cells (biics) in bioreactors
|
|
WO2020223280A1
(en)
|
2019-04-29 |
2020-11-05 |
Voyager Therapeutics, Inc. |
Aav variants with enhanced tropism
|
|
SG11202111375RA
(en)
*
|
2019-04-29 |
2021-11-29 |
Univ Pennsylvania |
Novel aav capsids and compositions containing same
|
|
KR20220020261A
(ko)
|
2019-05-03 |
2022-02-18 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
이염성 백질이영양증의 치료에 유용한 조성물
|
|
US20240124889A1
(en)
|
2019-05-07 |
2024-04-18 |
Voyager Therapeutics, Inc. |
Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
|
|
TW202104592A
(zh)
|
2019-05-14 |
2021-02-01 |
美商拜奧馬林製藥公司 |
重複投予基因療法載體之方法
|
|
MX2021014478A
(es)
|
2019-05-28 |
2022-01-06 |
Astellas Pharma Inc |
Metodo para tratar distrofia muscular por direccionamiento del gen dmpk.
|
|
AU2020284255A1
(en)
|
2019-05-30 |
2022-01-06 |
Solid Biosciences Inc. |
Recombinant herpesvirales vector
|
|
EP3990030A1
(en)
|
2019-06-27 |
2022-05-04 |
Pfizer Inc. |
Methods of treating duchenne muscular dystrophy using aav mini-dystrophin gene therapy
|
|
US12492412B2
(en)
|
2019-07-02 |
2025-12-09 |
M6P Terapeutics (Switzerland) Llc |
Vector compositions and methods of using same for treatment of lysosomal storage disorders
|
|
EP3997225A1
(en)
|
2019-07-10 |
2022-05-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of epilepsy
|
|
EP3997214B1
(en)
|
2019-07-11 |
2023-08-02 |
Centre National de la Recherche Scientifique |
Chemically-modified adeno-associated virus
|
|
EP3997226A1
(en)
|
2019-07-11 |
2022-05-18 |
Tenaya Therapeutics, Inc. |
Cardiac cell reprogramming with micrornas and other factors
|
|
US10801042B1
(en)
|
2019-07-15 |
2020-10-13 |
Vigene Biosciences, Inc. |
Use of ion concentrations to increase the packaging efficiency of recombinant adeno-associated virus
|
|
US10653731B1
(en)
|
2019-07-15 |
2020-05-19 |
Vigene Biosciences Inc. |
Recombinantly-modified adeno-associated virus (rAAV) having improved packaging efficiency
|
|
US10557149B1
(en)
|
2019-07-15 |
2020-02-11 |
Vigene Biosciences, Inc. |
Recombinantly-modified adeno-associated virus helper vectors and their use to improve the packaging efficiency of recombinantly-modified adeno-associated virus
|
|
US20220267773A1
(en)
|
2019-07-23 |
2022-08-25 |
University Of Rochester |
Targeted RNA cleavage with CRISPR-Cas
|
|
EP4007814A1
(en)
|
2019-07-26 |
2022-06-08 |
Akouos, Inc. |
Methods of treating hearing loss using a secreted target protein
|
|
EP4004214A1
(en)
|
2019-07-26 |
2022-06-01 |
RegenxBio Inc. |
Engineered nucleic acid regulatory element and methods of uses thereof
|
|
EP4010465A1
(en)
|
2019-08-09 |
2022-06-15 |
Voyager Therapeutics, Inc. |
Cell culture medium for use in producing gene therapy products in bioreactors
|
|
US12502418B2
(en)
|
2019-08-16 |
2025-12-23 |
Modalis Therapeutics Corporation |
Method for treating muscular dystrophy by targeting LAMA1 gene
|
|
WO2021034920A1
(en)
*
|
2019-08-20 |
2021-02-25 |
St. Jude Children's Research Hospital, Inc. |
SCHIZOPHRENIA-RELATED MICRODELETION GENE 2510002D24Rik IS ESSENTIAL FOR SOCIAL MEMORY
|
|
CN114502197A
(zh)
|
2019-08-26 |
2022-05-13 |
再生生物股份有限公司 |
用全人经翻译后修饰的抗VEGF Fab治疗糖尿病性视网膜病变
|
|
US20220307013A1
(en)
|
2019-08-30 |
2022-09-29 |
The Regents Of The University Of California |
Gene fragment overexpression screening methodologies, and uses thereof
|
|
US20230092895A1
(en)
|
2019-08-30 |
2023-03-23 |
Obsidian Therapeutics, Inc. |
Tandem cd19 car-based compositions and methods for immunotherapy
|
|
WO2021046155A1
(en)
|
2019-09-03 |
2021-03-11 |
Voyager Therapeutics, Inc. |
Vectorized editing of nucleic acids to correct overt mutations
|
|
WO2021046451A1
(en)
|
2019-09-06 |
2021-03-11 |
Obsidian Therapeutics, Inc. |
Compositions and methods for dhfr tunable protein regulation
|
|
CA3153972A1
(en)
|
2019-09-09 |
2021-03-18 |
Massachusetts Eye And Ear Infirmary |
Methods and compositions for modulating the interaction between adeno-associated virus (aav) and the aav receptor (aavr) for altered bio-distribution of aav
|
|
AU2020346062A1
(en)
|
2019-09-13 |
2022-03-24 |
Rutgers, The State University Of New Jersey |
AAV-compatible laminin-linker polymerization proteins
|
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與ｅｎｔｐｄ２抗體之組合療法
|
|
CN114502590A
(zh)
|
2019-09-18 |
2022-05-13 |
诺华股份有限公司 |
Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
|
|
JP7651562B2
(ja)
|
2019-09-19 |
2025-03-26 |
ジェネトン |
Ｆｋｒｐの心毒性を軽減する遺伝子治療発現系
|
|
WO2021055880A1
(en)
|
2019-09-20 |
2021-03-25 |
University Of Florida Researchfoundation, Incorporated |
Detection of antibodies against ran proteins from serum and tissue lysates
|
|
WO2021067598A1
(en)
|
2019-10-04 |
2021-04-08 |
Ultragenyx Pharmaceutical Inc. |
Methods for improved therapeutic use of recombinant aav
|
|
WO2021071835A1
(en)
|
2019-10-07 |
2021-04-15 |
Regenxbio Inc. |
Adeno-associated virus vector pharmaceutical composition and methods
|
|
KR20220076510A
(ko)
|
2019-10-08 |
2022-06-08 |
트러스티스 오브 보스톤 칼리지 |
다수의 서로 다른 비천연 아미노산을 함유하는 단백질 및 이러한 단백질의 제조 및 사용 방법
|
|
US20220362402A1
(en)
|
2019-10-08 |
2022-11-17 |
Exhaura, Ltd. |
Compositions and methods for ocular therapy
|
|
EP4450514A3
(en)
|
2019-10-14 |
2025-04-09 |
Duke University |
Compositions comprising novel prokaryotic sodium channels and associated methods
|
|
US12611436B2
(en)
|
2019-10-17 |
2026-04-28 |
Sarepta Therapeutics, Inc. |
AAV transfer cassette
|
|
JP2022551739A
(ja)
|
2019-10-17 |
2022-12-13 |
ストライドバイオ，インコーポレイテッド |
ニーマン・ピック病ｃ型の治療のためのアデノ随伴ウイルスベクター
|
|
WO2021092300A1
(en)
*
|
2019-11-08 |
2021-05-14 |
President And Fellows Of Harvard College |
Viral capsid polypeptides
|
|
WO2021092298A1
(en)
*
|
2019-11-08 |
2021-05-14 |
President And Fellows Of Harvard College |
Viral capsid polypeptides
|
|
US20230016983A1
(en)
|
2019-11-19 |
2023-01-19 |
lNSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) |
Antisense oligonucleotides and thier use for the treatment of cancer
|
|
TWI908746B
(zh)
*
|
2019-11-28 |
2025-12-21 |
美商銳進科斯生物股份有限公司 |
微小肌縮蛋白基因療法之構築體及其用途
|
|
EP4069856A1
(en)
*
|
2019-12-04 |
2022-10-12 |
Sangamo Therapeutics, Inc. |
Novel compositions and methods for producing recombinant aav
|
|
EP4073257A1
(en)
|
2019-12-09 |
2022-10-19 |
UCL Business Ltd |
Gene therapy composition and treatment for myh7-linked cardiomyopathy
|
|
AU2020401116A1
(en)
|
2019-12-10 |
2022-07-21 |
Takeda Pharmaceutical Company Limited |
Adeno associated virus vectors for the treatment of Hunter disease
|
|
CA3162020A1
(en)
|
2019-12-19 |
2021-06-24 |
James M. Wilson |
Compositions for treating friedreich's ataxia
|
|
WO2021138559A1
(en)
|
2019-12-31 |
2021-07-08 |
Swanbio Therapeutics Limited |
Improved aav-abcd1 constructs and use for treatment or prevention of adrenoleukodystrophy (ald) and/or adrenomyeloneuropathy (amn)
|
|
EP4087489B1
(en)
|
2020-01-08 |
2025-05-14 |
Vitruvia Holdings Inc. |
Methods and computing system for processing ultrasound image to determine health of subdermal tissue
|
|
TW202140791A
(zh)
|
2020-01-13 |
2021-11-01 |
美商霍蒙拉奇醫藥公司 |
治療苯酮尿症之方法
|
|
KR20220131522A
(ko)
|
2020-01-22 |
2022-09-28 |
리젠엑스바이오 인크. |
완전-인간 글리코실화된 인간 알파-l-이두로니다아제 (idua)를 사용한 점액다당류증 i의 치료
|
|
CA3168251A1
(en)
|
2020-01-29 |
2021-08-05 |
Regenxbio Inc. |
Treatment of mucopolysaccharidosis iva
|
|
BR112022015183A2
(pt)
|
2020-01-29 |
2022-12-20 |
Regenxbio Inc |
Método para tratamento de um sujeito humano diagnosticado com mucopolissacaridose tipo ii (mps ii)
|
|
KR20220145838A
(ko)
|
2020-02-02 |
2022-10-31 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
Gm1 강글리오사이드증을 치료하는 데 유용한 조성물
|
|
JP2023513211A
(ja)
|
2020-02-07 |
2023-03-30 |
ユニバーシティ オブ ロチェスター |
タンパク質合成を増強するためのＣＲＩＳＰＲ－Ｃａｓ１３による標的ＲＮＡ翻訳
|
|
EP4100533A1
(en)
|
2020-02-07 |
2022-12-14 |
University of Rochester |
Ribozyme-mediated rna assembly and expression
|
|
JP2023514204A
(ja)
|
2020-02-14 |
2023-04-05 |
ウルトラジェニックス ファーマシューティカル インコーポレイテッド |
Ｃｄｋｌ５欠損障害を処置するための遺伝子治療
|
|
JP2023515820A
(ja)
|
2020-02-28 |
2023-04-14 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
メープルシロップ尿症の遺伝子治療
|
|
US20230103731A1
(en)
|
2020-03-02 |
2023-04-06 |
Tenaya Therapeutics, Inc. |
Gene vector control by cardiomyocyte-expressed micrornas
|
|
CN115484978A
(zh)
|
2020-03-05 |
2022-12-16 |
尼奥克斯医疗有限公司 |
使用免疫细胞治疗癌症的方法和组合物
|
|
IL295810B2
(en)
|
2020-03-11 |
2026-01-01 |
Univ Pennsylvania |
Methods and compositions for gene delivery using a modified viral particle
|
|
US20230235353A1
(en)
*
|
2020-03-19 |
2023-07-27 |
Ultragenyx Pharmaceutical Inc. |
Compositions and methods for reducing reverse packaging of cap and rep sequences in recombinant aav
|
|
WO2021195519A1
(en)
|
2020-03-27 |
2021-09-30 |
University Of Rochester |
Targeted destruction of viral rna by crispr-cas13
|
|
IL296732A
(en)
|
2020-03-27 |
2022-11-01 |
UCB Biopharma SRL |
Autonomous knob domain peptides
|
|
WO2021195525A1
(en)
|
2020-03-27 |
2021-09-30 |
University Of Rochester |
Crispr-cas13 crrna arrays
|
|
WO2021202532A1
(en)
|
2020-03-31 |
2021-10-07 |
Ultragenyx Pharmaceutical Inc. |
Gene therapy for treating propionic acidemia
|
|
WO2021202651A1
(en)
|
2020-04-01 |
2021-10-07 |
Voyager Therapeutics, Inc. |
Redirection of tropism of aav capsids
|
|
KR20220167324A
(ko)
|
2020-04-10 |
2022-12-20 |
솔라 바이오사이언시즈 엘엘씨 |
단백질 응집 장애의 치료를 위한 조성물 및 방법
|
|
JP7713956B2
(ja)
|
2020-04-15 |
2025-07-28 |
ボイジャー セラピューティクス インコーポレイテッド |
タウ結合化合物
|
|
US12552838B2
(en)
*
|
2020-04-20 |
2026-02-17 |
Tenaya Therapeutics, Inc. |
Adeno-associated virus with engineered capsid
|
|
AU2021258194A1
(en)
|
2020-04-22 |
2022-11-24 |
Indapta Therapeutics, Inc. |
Natural killer (NK) cell compositions and methods for generating same
|
|
WO2021222168A2
(en)
|
2020-04-28 |
2021-11-04 |
Sola Biosciences Llc |
Compositions and methods for the treatment of tdp-43 proteinopathies
|
|
CA3177869A1
(en)
*
|
2020-05-05 |
2021-11-11 |
Duke University |
Cross-species compatible adeno-associated virus compositions and methods of use thereof
|
|
MX2022014258A
(es)
|
2020-05-12 |
2023-02-22 |
Univ Pennsylvania |
Composiciones para la reducción específica de un fármaco de la expresión de transgén.
|
|
CA3177924A1
(en)
|
2020-05-12 |
2021-11-18 |
The Trustees Of The University Of Pennsylvania |
Compositions useful in treatment of krabbe disease
|
|
TWI900553B
(zh)
|
2020-05-13 |
2025-10-11 |
美商航海家醫療公司 |
Aav蛋白殼之趨性重定向
|
|
WO2021231538A2
(en)
|
2020-05-13 |
2021-11-18 |
Akouos, Inc. |
Compositions and methods for treating kcnq4-associated hearing loss
|
|
IL298128A
(en)
|
2020-05-13 |
2023-01-01 |
Akouos Inc |
Compositions and methods for treating slc26a4-associated hearing loss
|
|
WO2021230385A1
(en)
|
2020-05-15 |
2021-11-18 |
Astellas Pharma Inc. |
Method for treating muscular dystrophy by targeting utrophin gene
|
|
WO2021236908A2
(en)
|
2020-05-20 |
2021-11-25 |
Biomarin Pharmaceutical Inc. |
Use of regulatory proteins for the production of adeno-associated virus
|
|
TW202208632A
(zh)
|
2020-05-27 |
2022-03-01 |
美商同源醫藥公司 |
用於恢復ｐａｈ基因功能的腺相關病毒組成物及其使用方法
|
|
WO2021247995A2
(en)
|
2020-06-04 |
2021-12-09 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating neuropathic pain
|
|
CA3183251A1
(en)
|
2020-06-05 |
2021-12-09 |
Sola Biosciences Llc |
Compositions and methods for the treatment of synucleinopathies
|
|
AU2021292200A1
(en)
|
2020-06-17 |
2023-02-02 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treatment of gene therapy patients
|
|
US20230256117A1
(en)
|
2020-06-19 |
2023-08-17 |
Genethon |
Gene therapy expression system allowing an adequate expression in the muscles and in the heart of sgcg
|
|
CA3187635A1
(en)
*
|
2020-07-03 |
2022-01-06 |
Genethon |
Method for engineering novel hybrid aav capsids through hypervariable regions swapping
|
|
MX2023000318A
(es)
*
|
2020-07-07 |
2023-02-09 |
Univ Texas |
Vector de virus adenoasociado para marco de lectura abierto peque?o.
|
|
KR20230050336A
(ko)
|
2020-07-10 |
2023-04-14 |
인스티튜트 내셔널 드 라 싼테 에 드 라 리셰르셰 메디칼르 (인 썸) |
뇌전증을 치료하기 위한 방법과 조성물
|
|
EP4179096A1
(en)
|
2020-07-10 |
2023-05-17 |
Genethon |
A novel muscle-specific promoter
|
|
IL299762A
(en)
|
2020-07-13 |
2023-03-01 |
Univ Pennsylvania |
Useful preparations for the treatment of Charcot-Marietot disease
|
|
CA3185589A1
(en)
|
2020-07-15 |
2022-01-20 |
Douglas Matthew ANDERSON |
Targeted rna cleavage with dcasl3-rnase fusion proteins
|
|
WO2022026410A2
(en)
|
2020-07-27 |
2022-02-03 |
Voyager Therapeutics, Inc |
Compositions and methods for the treatment of niemann-pick type c1 disease
|
|
BR112023001456A2
(pt)
|
2020-07-27 |
2023-04-11 |
Voyager Therapeutics Inc |
Composições e métodos para o tratamento de distúrbios neurológicos relacionados à deficiência de beta glicosilceramidase
|
|
CN111876432B
(zh)
*
|
2020-07-29 |
2022-10-28 |
舒泰神（北京）生物制药股份有限公司 |
一组肝靶向新型腺相关病毒的获得及其应用
|
|
WO2022032153A1
(en)
|
2020-08-06 |
2022-02-10 |
Voyager Therapeutics, Inc. |
Cell culture medium for use in producing gene therapy products in bioreactors
|
|
CN116406305A
(zh)
|
2020-08-17 |
2023-07-07 |
麻省理工学院 |
Shank3基因治疗方法
|
|
AU2021328475A1
(en)
|
2020-08-19 |
2023-03-16 |
Sarepta Therapeutics, Inc. |
Adeno-associated virus vectors for treatment of Rett syndrome
|
|
CA3190399A1
(en)
|
2020-08-24 |
2022-03-03 |
James M. Wilson |
Viral vectors encoding glp-1 receptor agonist fusions and uses thereof in treating metabolic diseases
|
|
EP4204014A1
(en)
|
2020-08-26 |
2023-07-05 |
The Trustees of The University of Pennsylvania |
Recombinant adeno-associated virus for treatment of grn-associated adult-onset neurodegeneration
|
|
CN116134141A
(zh)
|
2020-09-04 |
2023-05-16 |
国立大学法人神户大学 |
包含小型化胞苷脱氨酶的双链dna修饰用复合体
|
|
WO2022060916A1
(en)
|
2020-09-15 |
2022-03-24 |
Regenxbio Inc. |
Vectorized antibodies for anti-viral therapy
|
|
WO2022060915A1
(en)
|
2020-09-15 |
2022-03-24 |
Regenxbio Inc. |
Vectorized lanadelumab and administration thereof
|
|
US20230383278A1
(en)
|
2020-09-18 |
2023-11-30 |
The United States Of America,As Represented By The Secretary,Department Of Health And Human Services |
Novel adeno-associated viral (aav) vectors to treat hereditary methylmalonic acidemia (mma) caused by methylmalonyl-coa mutase (mmut) deficiency
|
|
MX2023003699A
(es)
|
2020-10-07 |
2023-04-21 |
Regenxbio Inc |
Virus adenoasociados para el suministro ocular de genoterapia.
|
|
KR20230106598A
(ko)
|
2020-10-07 |
2023-07-13 |
리젠엑스바이오 인크. |
겔 제형과 같은 맥락막위 투여용 제형
|
|
WO2022076750A2
(en)
|
2020-10-07 |
2022-04-14 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns or muscle delivery
|
|
CA3198372A1
(en)
|
2020-10-07 |
2022-04-14 |
Regenxbio Inc. |
Formulations for suprachoroidal administration such as high viscosity formulations
|
|
AU2021358781A1
(en)
|
2020-10-07 |
2023-05-18 |
Tern Therapeutics, Llc |
Gene therapy for ocular manifestations of cln2 disease
|
|
CA3198368A1
(en)
|
2020-10-07 |
2022-04-14 |
Regenxbio Inc. |
Formulations for suprachoroidal administration such as formulations with aggregate formation
|
|
AU2021356684A1
(en)
|
2020-10-09 |
2023-05-11 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treatment of fabry disease
|
|
US11781156B2
(en)
|
2020-10-09 |
2023-10-10 |
Tenaya Therapeutics, Inc. |
Plakophillin-2 gene therapy methods and compositions
|
|
BR112023006305A2
(pt)
|
2020-10-09 |
2023-05-09 |
Tenaya Therapeutics Inc |
Métodos e composições de terapia gênica com placofilina-2
|
|
WO2022082109A1
(en)
|
2020-10-18 |
2022-04-21 |
The Trustees Of The University Of Pennsylvania |
Improved adeno-associated virus (aav) vector and uses therefor
|
|
CA3195967A1
(en)
|
2020-10-28 |
2022-05-05 |
Xu Wang |
Vectorized anti-tnf-? antibodies for ocular indications
|
|
WO2022094157A1
(en)
|
2020-10-28 |
2022-05-05 |
Regenxbio Inc. |
Vectorized anti-cgrp and anti-cgrpr antibodies and administration thereof
|
|
WO2022094078A1
(en)
|
2020-10-28 |
2022-05-05 |
The Trustees Of The University Of Pennsylvania |
Compositions useful in treatment of rett syndrome
|
|
JP2023550581A
(ja)
*
|
2020-10-29 |
2023-12-04 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
Ａａｖカプシド及びそれを含有する組成物
|
|
AU2021369833A1
(en)
|
2020-10-29 |
2023-06-08 |
Regenxbio Inc. |
Vectorized tnf-alpha antagonists for ocular indications
|
|
US20230390418A1
(en)
|
2020-10-29 |
2023-12-07 |
Regenxbio Inc. |
Vectorized factor xii antibodies and administration thereof
|
|
US20230407328A1
(en)
|
2020-11-02 |
2023-12-21 |
Biomarin Pharmaceutical Inc. |
Process for enriching adeno-associated virus
|
|
AU2021375404A1
(en)
|
2020-11-03 |
2023-06-08 |
Pfizer Inc. |
Methods for purification of aav vectors by anion exchange chromatography
|
|
IL303239A
(en)
|
2020-12-01 |
2023-07-01 |
Univ Pennsylvania |
Compositions and their uses for the treatment of Engelmann syndrome
|
|
IL303317A
(en)
|
2020-12-01 |
2023-07-01 |
Akouos Inc |
ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA
|
|
TW202237850A
(zh)
|
2020-12-01 |
2022-10-01 |
賓州大學委員會 |
具有組織特異性靶向基序的新穎構成物及含有其之組成物
|
|
US20240052322A1
(en)
|
2020-12-15 |
2024-02-15 |
Pfizer Inc. |
HILIC UPLC-MS Method For Separating and Analyzing Intact Adeno-Associated Virus Capsid Proteins
|
|
EP4263841A1
(en)
|
2020-12-16 |
2023-10-25 |
REGENXBIO Inc. |
Method of producing a recombinant adeno-associated virus particle
|
|
IL303959A
(en)
|
2020-12-23 |
2023-08-01 |
Pfizer |
Methods for purification of aav vectors by affinity chromatography
|
|
TW202241943A
(zh)
|
2020-12-29 |
2022-11-01 |
美商銳進科斯生物股份有限公司 |
Tau特異性抗體基因療法組合物、方法及其用途
|
|
IL304006A
(en)
|
2020-12-29 |
2023-08-01 |
Akouos Inc |
Compositions and methods for treating hearing loss and/or vision loss associated with CLRN1
|
|
WO2022147480A1
(en)
|
2020-12-30 |
2022-07-07 |
Ansun Biopharma, Inc. |
Oncolytic virus encoding sialidase and multispecific immune cell engager
|
|
EP4277933A4
(en)
|
2021-01-14 |
2024-12-11 |
Senti Biosciences, Inc. |
SECRETABLE PAYLOAD REGULATION
|
|
JP2024503895A
(ja)
|
2021-01-21 |
2024-01-29 |
リジェネクスバイオ インコーポレイテッド |
組換えポリペプチド及びウイルスの生成の改善
|
|
MX2023008738A
(es)
*
|
2021-01-25 |
2023-09-12 |
Trames Bio Inc |
Cápsides de virus adenoasociados y canales iónicos controlados por ligandos diseñados para el tratamiento contra epilepsia focal y dolor neuropático.
|
|
WO2022165313A1
(en)
|
2021-02-01 |
2022-08-04 |
Regenxbio Inc. |
Gene therapy for neuronal ceroid lipofuscinoses
|
|
US11926842B2
(en)
*
|
2021-02-02 |
2024-03-12 |
University Of Massachusetts |
Use of inverted terminal repeats (ITRS) from adeno-associated virus serotypes 8 and RH.39 in gene therapy vectors
|
|
JP2024506296A
(ja)
|
2021-02-05 |
2024-02-13 |
メイズ セラピューティクス， インコーポレイテッド |
スタッファーポリヌクレオチド配列を含むベクター
|
|
US20240115734A1
(en)
*
|
2021-02-09 |
2024-04-11 |
Affinia Therapeutics Inc. |
Recombinant aavs with improved tropism and specificity
|
|
EP4291249A2
(en)
|
2021-02-10 |
2023-12-20 |
RegenxBio Inc. |
Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2-sulfatase (ids)
|
|
AR124981A1
(es)
|
2021-02-26 |
2023-05-24 |
Takeda Pharmaceuticals Co |
Composición y métodos para el tratamiento de la enfermedad de fabry
|
|
WO2022187548A1
(en)
|
2021-03-03 |
2022-09-09 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
WO2022187473A2
(en)
|
2021-03-03 |
2022-09-09 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
WO2022198038A1
(en)
|
2021-03-19 |
2022-09-22 |
Adrenas Therapeutics, Inc. |
Gene therapies for 21-hydroxylase deficiency
|
|
US20240307553A1
(en)
|
2021-04-01 |
2024-09-19 |
Pfizer Inc. |
Pharmaceutical compositions containing adeno-associated viral vector
|
|
EP4320139A1
(en)
|
2021-04-05 |
2024-02-14 |
Solid Biosciences Inc. |
Recombinant herpesvirales vector
|
|
IL307633A
(en)
|
2021-04-12 |
2023-12-01 |
Univ Pennsylvania |
Useful preparations in the treatment of spinal muscular atrophy (SBMA)
|
|
US20240181084A1
(en)
|
2021-04-23 |
2024-06-06 |
University Of Rochester |
Genome Editing by Directed Non-Homologous DNA Insertion Using a Retroviral Integrase-Cas Fusion Protein and Methods of Treatment
|
|
CA3216004A1
(en)
|
2021-04-23 |
2022-10-27 |
The Trustees Of The University Of Pennsylvania |
Novel compositions with brain-specific targeting motifs and compositions containing same
|
|
US20250188126A1
(en)
|
2021-04-26 |
2025-06-12 |
Alexion Pharma International Operations Limited |
Adeno-associated viral vector capsids with improved tissue tropism
|
|
JP2024517143A
(ja)
|
2021-04-26 |
2024-04-19 |
リジェネックスバイオ インコーポレイテッド |
ジストロフィン異常症の治療のためのマイクロジストロフィン遺伝子療法投与
|
|
US20240218397A1
(en)
|
2021-05-04 |
2024-07-04 |
Regenxbio Inc. |
Novel aav vectors and methods and uses thereof
|
|
EP4337267A1
(en)
|
2021-05-11 |
2024-03-20 |
RegenxBio Inc. |
Treatment of duchenne muscular dystrophy and combinations thereof
|
|
JP2024520815A
(ja)
*
|
2021-06-08 |
2024-05-24 |
エヌエフ２ セラピューティクス， インコーポレイテッド |
神経線維腫性障害を処置するための組成物および方法
|
|
JP2024522230A
(ja)
*
|
2021-06-18 |
2024-06-11 |
ダイノ セラピューティクス インコーポレイテッド |
カプシドバリアント及びそれを使用する方法
|
|
WO2022269466A1
(en)
|
2021-06-22 |
2022-12-29 |
Pfizer Inc. |
Production of adeno-associated virus vector in insect cells
|
|
US20240287493A1
(en)
*
|
2021-06-24 |
2024-08-29 |
University Of Utah Research Foundation |
Compositions and methods for treating pgm1 deficiency
|
|
US20240316102A1
(en)
|
2021-07-01 |
2024-09-26 |
Indapta Therapeutics, Inc. |
Engineered natural killer (nk) cells and related methods
|
|
KR20240032971A
(ko)
|
2021-07-08 |
2024-03-12 |
테나야 테라퓨틱스, 인코포레이티드 |
유전자 요법을 위한 최적화된 발현 카세트
|
|
US20240409955A1
(en)
|
2021-07-19 |
2024-12-12 |
New York University |
Auf1 combination therapies for treatment of muscle degenerative disease
|
|
EP4359551A4
(en)
*
|
2021-07-23 |
2025-09-24 |
Univ Duke |
ADENO-ASSOCIATED VIRUS COMPOSITIONS AND METHODS OF USE THEREOF
|
|
CA3227533A1
(en)
|
2021-07-30 |
2023-02-02 |
Toru Miyazaki |
Therapeutic agent for ischemic disease
|
|
AU2022325232A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified primary cells for allogeneic cell therapy
|
|
EP4384598A1
(en)
|
2021-08-11 |
2024-06-19 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
|
|
JP2024535677A
(ja)
|
2021-08-11 |
2024-10-02 |
サナ バイオテクノロジー，インコーポレイテッド |
即時血液媒介性炎症反応を減少させるための同種細胞療法を目的とした遺伝子改変細胞
|
|
US20240358761A1
(en)
|
2021-08-11 |
2024-10-31 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy
|
|
AR126839A1
(es)
*
|
2021-08-20 |
2023-11-22 |
Llc «Anabion» |
Proteína de la cápside vp1 modificada aislada del virus adeno-asociado de serotipo 9 (aav9), cápside y vector basado en esta
|
|
CA3229998A1
(en)
*
|
2021-08-25 |
2023-03-02 |
Canbridge Pharmaceuticals, Inc. |
Aav particles comprising a liver-tropic capsid protein and alpha-galactosidase and their use to treat fabry disease
|
|
AR126877A1
(es)
*
|
2021-08-25 |
2023-11-22 |
Canbridge Pharmaceuticals Inc |
PARTÍCULAS DE AAV QUE COMPRENDEN UNA PROTEÍNA DE LA CÁPSIDE HEPATOTRÓPICA Y a-GLUCOSIDASA ÁCIDA (GAA) Y SU USO PARA TRATAR LA ENFERMEDAD DE POMPE
|
|
KR20240107201A
(ko)
|
2021-08-31 |
2024-07-08 |
스카우트 바이오, 인코포레이티드 |
항원-결합 분자 및 이의 용도
|
|
WO2023044483A2
(en)
|
2021-09-20 |
2023-03-23 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
JP2024537775A
(ja)
|
2021-09-30 |
2024-10-16 |
アコーオス インコーポレイテッド |
Ｋｃｎｑ４関連難聴を治療するための組成物及び方法
|
|
EP4409010A1
(en)
|
2021-10-02 |
2024-08-07 |
The Trustees of The University of Pennsylvania |
Novel aav capsids and compositions containing same
|
|
CN118202060A
(zh)
|
2021-10-05 |
2024-06-14 |
再生生物股份有限公司 |
用于重组aav生产的组合物和方法
|
|
WO2023060113A1
(en)
|
2021-10-05 |
2023-04-13 |
Regenxbio Inc. |
Compositions and methods for recombinant aav production
|
|
WO2023060272A2
(en)
|
2021-10-07 |
2023-04-13 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns tropic delivery
|
|
WO2023060269A1
(en)
|
2021-10-07 |
2023-04-13 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for targeted delivery
|
|
US20230151372A1
(en)
*
|
2021-10-07 |
2023-05-18 |
Academia Sinica |
Composition and Method of Treatment for Heart Protection and Regeneration
|
|
CA3234720A1
(en)
|
2021-10-08 |
2023-04-13 |
Sola Biosciences Llc |
Compositions and methods for the treatment of p53-mediated cancers
|
|
KR20240095539A
(ko)
|
2021-10-08 |
2024-06-25 |
디노 테라퓨틱스, 인코포레이티드 |
캡시드 변이체 및 이의 사용 방법
|
|
WO2023060221A2
(en)
|
2021-10-08 |
2023-04-13 |
Sola Biosciences Llc |
Compositions and methods for the treatment of proteopathies
|
|
AU2022366947A1
(en)
|
2021-10-12 |
2024-05-02 |
Bridgebio Gene Therapy Llc |
Methods and compositions for treating leukodystrophies
|
|
CA3234809A1
(en)
|
2021-10-20 |
2023-04-27 |
Steven Goldman |
Isolated glial progenitor cells for use in the competition treatment of age-related white matter loss
|
|
US20250025574A1
(en)
|
2021-10-28 |
2025-01-23 |
Regenxbio Inc. |
Engineered nucleic acid regulatory elements and methods and uses thereof
|
|
EP4426331A1
(en)
|
2021-11-02 |
2024-09-11 |
University of Rochester |
Tcf7l2 mediated remyelination in the brain
|
|
EP4426716A1
(en)
|
2021-11-02 |
2024-09-11 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
US20250295807A1
(en)
|
2021-11-15 |
2025-09-25 |
The Trustees Of The University Of Pennsylvania |
Compositions for drg-specific reduction of transgene expression
|
|
US20250049955A1
(en)
|
2021-11-17 |
2025-02-13 |
Voyager Therapeutics, Inc. |
Compositons and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
|
US20250034559A1
(en)
|
2021-11-17 |
2025-01-30 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
EP4433169A1
(en)
|
2021-11-17 |
2024-09-25 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
TW202325850A
(zh)
|
2021-11-29 |
2023-07-01 |
大陸商上海瑞宏迪醫藥有限公司 |
Aadc、gdnf多核苷酸及其用於治療帕金森病
|
|
US20240408157A1
(en)
|
2021-12-02 |
2024-12-12 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treatment of fabry disease
|
|
WO2023114816A1
(en)
|
2021-12-14 |
2023-06-22 |
Neurogene, Inc. |
Recombinant optimized galc constructs and methods for treating galc-associated disorders
|
|
WO2023114897A2
(en)
*
|
2021-12-15 |
2023-06-22 |
Homology Medicines, Inc. |
Methods and compositions for the production of adeno-associated virus
|
|
WO2023133584A1
(en)
|
2022-01-10 |
2023-07-13 |
The Trustees Of The University Of Pennsylvania |
Compositions useful in treatment of metachromatic leukodystrophy
|
|
EP4463135A2
(en)
|
2022-01-10 |
2024-11-20 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
WO2023133574A1
(en)
|
2022-01-10 |
2023-07-13 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods useful for treatment of c9orf72-mediated disorders
|
|
CN119233831A
(zh)
|
2022-01-17 |
2024-12-31 |
迪纳柯公司 |
用于与肌营养不良蛋白有关的心肌病的基因疗法组合物和治疗
|
|
EP4215614A1
(en)
|
2022-01-24 |
2023-07-26 |
Dynacure |
Combination therapy for dystrophin-related diseases
|
|
CN119317718A
(zh)
|
2022-01-25 |
2025-01-14 |
宾夕法尼亚州大学信托人 |
用于改善心脏转导和肝脏去靶向的aav衣壳
|
|
WO2023147374A2
(en)
|
2022-01-25 |
2023-08-03 |
Voyager Therapeutics, Inc. |
Baculovirus expression system
|
|
GB202201242D0
(en)
|
2022-01-31 |
2022-03-16 |
Univ Edinburgh |
Recombinant optimized mecp2 cassettes and methods for treating rett syndrome and related disorders
|
|
WO2023150647A1
(en)
|
2022-02-02 |
2023-08-10 |
Sana Biotechnology, Inc. |
Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
TW202342525A
(zh)
|
2022-02-02 |
2023-11-01 |
美商阿科奧斯公司 |
用於治療前庭神經鞘瘤相關症狀之抗ｖｅｇｆ抗體構築體及相關方法
|
|
CA3249551A1
(en)
|
2022-02-08 |
2023-08-17 |
Voyager Therapeutics, Inc. |
AAV Capsid Variants and Their Uses
|
|
EP4479416A1
(en)
|
2022-02-17 |
2024-12-25 |
Sana Biotechnology, Inc. |
Engineered cd47 proteins and uses thereof
|
|
AU2023220237A1
(en)
|
2022-02-21 |
2024-08-15 |
Shanghai Regenelead Therapies Co., Ltd |
Vegf-binding molecule and pharmaceutical use thereof
|
|
EP4482970A1
(en)
|
2022-02-23 |
2025-01-01 |
Massachusetts Institute of Technology |
Methods for upregulating shank3 expression
|
|
WO2023173123A1
(en)
|
2022-03-11 |
2023-09-14 |
Sana Biotechnology, Inc. |
Genetically modified cells and compositions and uses thereof
|
|
WO2023178053A1
(en)
|
2022-03-13 |
2023-09-21 |
Regenxbio Inc. |
Modified muscle-specific promoters
|
|
US20250213727A1
(en)
|
2022-03-25 |
2025-07-03 |
Regenxbio Inc. |
Dominant-negative tumor necrosis factor alpha adeno-associated virus gene therapy
|
|
CN119301262A
(zh)
|
2022-04-01 |
2025-01-10 |
武田药品工业株式会社 |
用于具有cns表现的疾病的基因疗法
|
|
WO2023196892A1
(en)
|
2022-04-06 |
2023-10-12 |
The Trustees Of The University Of Pennsylvania |
Passive immunization with anti- aav neutralizing antibodies to prevent off-target transduction of intrathecally delivered aav vectors
|
|
US20260034243A1
(en)
|
2022-04-06 |
2026-02-05 |
Regenxbio Inc. |
Pharmaceutical composition comprising a recombinant adeno-associated virus vector with an expression cassette encoding a transgene for suprachoroidal administration
|
|
TW202345913A
(zh)
|
2022-04-06 |
2023-12-01 |
美商銳進科斯生物股份有限公司 |
用於脈絡膜上投與之調配物諸如凝膠調配物
|
|
EP4504797A1
(en)
|
2022-04-06 |
2025-02-12 |
The Trustees of The University of Pennsylvania |
Compositions and methods for treating her2 positive metastatic breast cancer and other cancers
|
|
TW202404651A
(zh)
|
2022-04-06 |
2024-02-01 |
美商銳進科斯生物股份有限公司 |
用於脈絡膜上投與之調配物諸如形成聚集體之調配物
|
|
WO2023198652A1
(en)
|
2022-04-11 |
2023-10-19 |
Centre National De La Recherche Scientifique |
Chemically-modified adeno-associated viruses
|
|
WO2023201207A1
(en)
|
2022-04-11 |
2023-10-19 |
Tenaya Therapeutics, Inc. |
Adeno-associated virus with engineered capsid
|
|
WO2023201277A1
(en)
|
2022-04-14 |
2023-10-19 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns tropic delivery
|
|
US20250249127A1
(en)
|
2022-04-14 |
2025-08-07 |
Regenxbio Inc. |
Gene therapy for treating an ocular disease
|
|
US20250277004A1
(en)
|
2022-04-18 |
2025-09-04 |
Regenxbio Inc. |
Hybrid aav capsids
|
|
GB202206336D0
(en)
|
2022-04-29 |
2022-06-15 |
Univ Edinburgh |
Recombinant therapeutic FMR1 constructs and methods of treating fragile X syndrome and related disorders
|
|
US20260034246A1
(en)
|
2022-05-03 |
2026-02-05 |
Regenxbio Inc. |
Vectorized anti-complement antibodies and complement agents and administration thereof
|
|
WO2023215807A1
(en)
|
2022-05-03 |
2023-11-09 |
Regenxbio Inc. |
VECTORIZED ANTI-TNF-α INHIBITORS FOR OCULAR INDICATIONS
|
|
US20250353883A1
(en)
|
2022-05-06 |
2025-11-20 |
Novartis Ag |
Novel recombinant aav vp2 fusion polypeptides
|
|
WO2023220695A2
(en)
|
2022-05-13 |
2023-11-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
CN119630687A
(zh)
*
|
2022-05-24 |
2025-03-14 |
凯特治疗学股份有限公司 |
用于治疗xlmtm的组合物
|
|
EP4532515A1
(en)
|
2022-06-02 |
2025-04-09 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
WO2023240158A2
(en)
*
|
2022-06-07 |
2023-12-14 |
Oregon Health & Science University |
Mutant adeno-associated virus (aav) capsids
|
|
WO2023239627A2
(en)
|
2022-06-08 |
2023-12-14 |
Regenxbio Inc. |
Methods for recombinant aav production
|
|
WO2023240236A1
(en)
|
2022-06-10 |
2023-12-14 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of spinal muscular atrophy related disorders
|
|
IL317874A
(en)
|
2022-06-24 |
2025-02-01 |
Tune Therapeutics Inc |
Compounds, systems and methods for reducing low density lipoproteins through targeted gene suppression
|
|
CA3259902A1
(en)
|
2022-06-28 |
2024-01-04 |
Voyager Therapeutics, Inc. |
AAV Capsid Variants and Their Uses
|
|
WO2024003687A1
(en)
|
2022-06-28 |
2024-01-04 |
Pfizer Inc. |
Nucleic acids encoding acid alpha-glucosidase (gaa) and vectors for gene therapy
|
|
JP2025525439A
(ja)
|
2022-06-30 |
2025-08-05 |
インダプタ セラピューティクス インコーポレイテッド |
操作されたナチュラルキラー（ｎｋ）細胞と抗体療法との組み合わせおよび関連する方法
|
|
US20250388626A1
(en)
|
2022-07-06 |
2025-12-25 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
WO2024017990A1
(en)
|
2022-07-21 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Methods and compositions for treating chronic pain disorders
|
|
WO2024026377A1
(en)
|
2022-07-27 |
2024-02-01 |
Sana Biotechnology, Inc. |
Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
|
|
JP2025528068A
(ja)
|
2022-08-03 |
2025-08-26 |
ボイジャー セラピューティクス インコーポレイテッド |
血液脳関門を通過させるための組成物及び方法
|
|
WO2024038365A1
(en)
|
2022-08-16 |
2024-02-22 |
Pfizer Inc. |
Methods for purification of aav vectors by anion exchange chromatography
|
|
US20260055144A1
(en)
|
2022-08-24 |
2026-02-26 |
Regenxbio Inc. |
Recombinant adeno-associated viruses and uses thereof
|
|
AU2023331251A1
(en)
|
2022-08-25 |
2025-02-27 |
Takeda Pharmaceutical Company Limited |
Composition for use in the treatment of fabry disease
|
|
US20260085328A1
(en)
|
2022-09-08 |
2026-03-26 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
TW202421788A
(zh)
|
2022-09-22 |
2024-06-01 |
美商拜奧馬林製藥公司 |
用ａａｖ基因療法載體治療致心律不整性心肌病
|
|
CN120380156A
(zh)
|
2022-09-22 |
2025-07-25 |
迪纳柯公司 |
用aav基因治疗载体治疗心肌病
|
|
IL319873A
(en)
|
2022-09-30 |
2025-05-01 |
Regenxbio Inc |
Treatment of eye diseases with recombinant viral vectors containing anti-VEGF FAB
|
|
WO2024077089A2
(en)
*
|
2022-10-04 |
2024-04-11 |
Siren Biotechnology, Inc. |
Modified cpg dinucleotides for recombinant viral vector production
|
|
EP4601710A2
(en)
|
2022-10-11 |
2025-08-20 |
RegenxBio Inc. |
Engineered nucleic acid regulatory elements and methods and uses thereof
|
|
WO2024105638A1
(en)
|
2022-11-18 |
2024-05-23 |
Jcr Pharmaceuticals Co., Ltd. |
Recombinant aav vectors and methods for treatment of hunter syndrome
|
|
EP4634394A2
(en)
|
2022-12-17 |
2025-10-22 |
The Trustees of The University of Pennsylvania |
Recombinant aav mutant vectors with cardiac and skeletal muscle-specific targeting motifs and compositions containing same
|
|
WO2024130070A2
(en)
|
2022-12-17 |
2024-06-20 |
The Trustees Of The University Of Pennsylvania |
Recombinant aav capsids with cardiac- and skeletal muscle- specific targeting motifs and uses thereof
|
|
IT202200026595A1
(it)
|
2022-12-22 |
2024-06-22 |
Fond Telethon Ets |
Nuovi inibitori di regolatori epigenetici
|
|
EP4646478A1
(en)
|
2023-01-06 |
2025-11-12 |
Institut National de la Santé et de la Recherche Médicale |
Intravenous administration of antisense oligonucleotides for the treatment of pain
|
|
WO2024151541A1
(en)
|
2023-01-09 |
2024-07-18 |
Sana Biotechnology, Inc. |
Type-1 diabetes autoimmune mouse
|
|
WO2024149844A1
(en)
|
2023-01-12 |
2024-07-18 |
Nantes Université |
Chemically-modified adeno-associated virus
|
|
WO2024163979A2
(en)
*
|
2023-02-02 |
2024-08-08 |
Codexis, Inc. |
Engineered aav polypeptides
|
|
AU2023427408A1
(en)
|
2023-02-02 |
2025-09-04 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
|
EP4658294A2
(en)
|
2023-02-02 |
2025-12-10 |
University of Rochester |
Competitive replacement of glial cells
|
|
WO2024173802A2
(en)
|
2023-02-17 |
2024-08-22 |
Biogen Ma Inc. |
Rgd-containing peptides for delivering payloads
|
|
EP4680741A2
(en)
|
2023-03-15 |
2026-01-21 |
RegenxBio Inc. |
Exon skipping gene therapy constructs, vectors and uses thereof
|
|
CN120882872A
(zh)
|
2023-03-17 |
2025-10-31 |
罗切斯特大学 |
核酶介导的rna组装和表达
|
|
WO2024206226A1
(en)
*
|
2023-03-25 |
2024-10-03 |
Duke University |
Compositions comprising kidney-tropic aavs and methods of use thereof
|
|
WO2024211780A1
(en)
|
2023-04-07 |
2024-10-10 |
Regenxbio Inc. |
Compositions and methods for recombinant aav production
|
|
WO2024215655A1
(en)
|
2023-04-10 |
2024-10-17 |
Tenaya Therapeutics, Inc. |
Cardioprotective bag3 therapies
|
|
WO2024215653A1
(en)
|
2023-04-10 |
2024-10-17 |
Tenaya Therapeutics, Inc. |
Guide rnas, vectors, and virions for targeting mutations in the pln gene
|
|
WO2024216244A2
(en)
|
2023-04-13 |
2024-10-17 |
Regenxbio Inc. |
Targeting aav capsids, methods of manufacturing and using same
|
|
WO2024220463A2
(en)
*
|
2023-04-17 |
2024-10-24 |
University Of Massachusetts |
Aav5 capsid with non-canonical amino acid incorporation and uses thereof
|
|
WO2024220389A2
(en)
*
|
2023-04-17 |
2024-10-24 |
University Of Massachusetts |
Aav2 variants and uses thereof
|
|
WO2024218192A1
(en)
|
2023-04-18 |
2024-10-24 |
Uniqure Biopharma B.V. |
Novel neurotropic adeno-associated virus capsids with detargeting of peripheral organs
|
|
AU2024258816A1
(en)
|
2023-04-18 |
2025-10-23 |
Uniqure Biopharma B.V. |
Generation of adeno-associated virus capsid libraries for insect cells
|
|
WO2024226790A1
(en)
|
2023-04-26 |
2024-10-31 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
WO2024226761A2
(en)
|
2023-04-26 |
2024-10-31 |
Voyager Therapeutics, Inc. |
Compositions and methods for treating amyotrophic lateral sclerosis
|
|
AU2024264889A1
(en)
|
2023-05-03 |
2025-11-13 |
Sana Biotechnology, Inc. |
Methods of dosing and administration of engineered islet cells
|
|
AU2024266519A1
(en)
|
2023-05-03 |
2025-12-04 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to syntaxin-binding protein 1 deficiency
|
|
EP4705484A1
(en)
|
2023-05-03 |
2026-03-11 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
KR20260021096A
(ko)
|
2023-05-03 |
2026-02-12 |
보이저 테라퓨틱스, 인크. |
Cdkl5 결핍과 관련된 장애의 치료를 위한 조성물 및 방법
|
|
WO2024229309A2
(en)
|
2023-05-03 |
2024-11-07 |
Manifold Biotechnologies, Inc. |
Methodsand compositions for high-throughput protein delivery, screening, and detection
|
|
EP4705487A2
(en)
|
2023-05-03 |
2026-03-11 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to frataxin deficiency
|
|
TW202444917A
(zh)
|
2023-05-04 |
2024-11-16 |
美商航海家醫療公司 |
Ａａｖ衣殼變異體及其用途
|
|
WO2024233422A1
(en)
|
2023-05-05 |
2024-11-14 |
Massachusetts Institute Of Technology |
Shank3 gene therapy approaches
|
|
WO2024233529A2
(en)
|
2023-05-07 |
2024-11-14 |
Regenxbio Inc. |
Compositions and methods for recombinant aav production
|
|
KR20260010739A
(ko)
|
2023-05-11 |
2026-01-21 |
유니버시티 하스피탈즈 클리블랜드 메디컬 센터 |
항불안 치료
|
|
WO2024238853A1
(en)
|
2023-05-16 |
2024-11-21 |
Regenxbio Inc. |
Adeno-associated viruses for ocular delivery of gene therapy
|
|
WO2024238859A1
(en)
|
2023-05-16 |
2024-11-21 |
Regenxbio Inc. |
Vectorized c5 inhibitor agents and administration thereof
|
|
WO2024238867A1
(en)
|
2023-05-16 |
2024-11-21 |
Regenxbio Inc. |
Vectorized anti-complement antibodies and administration thereof
|
|
EP4716541A2
(en)
|
2023-05-22 |
2026-04-01 |
Sana Biotechnology, Inc. |
Methods of delivery of islet cells and related methods
|
|
WO2024241176A1
(en)
|
2023-05-24 |
2024-11-28 |
Jcr Pharmaceuticals Co., Ltd. |
Recombinant aav vectors and methods for treatment of diseases with central nervous system disorders
|
|
WO2024258961A1
(en)
|
2023-06-12 |
2024-12-19 |
The Trustees Of The University Of Pennsylvania |
Aav gene therapy for mucopolysaccharidosis iiib
|
|
TW202516019A
(zh)
|
2023-06-29 |
2025-04-16 |
賓州大學委員會 |
具中樞神經系統靶向模體的突變aav及含有其之組成物
|
|
WO2025008406A1
(en)
|
2023-07-04 |
2025-01-09 |
Institut National de la Santé et de la Recherche Médicale |
Antisense oligonucleotides and their use for the treatment of cancer
|
|
WO2025017168A1
(en)
|
2023-07-19 |
2025-01-23 |
Genethon |
Novel optimized utrophin micro-genes
|
|
CN121605119A
(zh)
|
2023-07-20 |
2026-03-03 |
吉尼松公司 |
新的中型肌营养不良蛋白
|
|
IL326390A
(en)
|
2023-08-10 |
2026-04-01 |
Univ Pennsylvania |
Compositions and methods for treating spinal muscular atrophy
|
|
WO2025042711A1
(en)
|
2023-08-18 |
2025-02-27 |
Eli Lilly And Company |
Engineered transferrin receptor binding peptides as well as methods of making and using the same
|
|
TW202508610A
(zh)
|
2023-08-23 |
2025-03-01 |
大陸商上海瑞宏迪醫藥有限公司 |
醫藥組成物及其用途
|
|
WO2025072604A1
(en)
|
2023-09-28 |
2025-04-03 |
University Of Rochester |
Rna-editing gene therapy approaches for treating myotonic dystrophy type 1 (dm1)
|
|
WO2025075963A1
(en)
|
2023-10-02 |
2025-04-10 |
Regenxbio Inc. |
Methods and formulations for treating mucopolysaccharidosis ii-associated hearing loss with recombinant human iduronate-2-sulfatase
|
|
WO2025080780A1
(en)
|
2023-10-10 |
2025-04-17 |
University Of Rochester |
Delivery and expression of prime editing crispr systems
|
|
WO2025090427A1
(en)
|
2023-10-23 |
2025-05-01 |
University Of Rochester |
Glial-targeted relief of hyperexcitability in neurodegenerative diseases
|
|
WO2025090962A1
(en)
|
2023-10-25 |
2025-05-01 |
Regenxbio Inc. |
Compositions and methods for recombinant aav production
|
|
WO2025090858A1
(en)
|
2023-10-27 |
2025-05-01 |
Biogen Ma Inc. |
Methods for identifying aav capsid variants with desired characteristics
|
|
TW202535908A
(zh)
|
2023-11-02 |
2025-09-16 |
美商渤健麻塞諸塞州股份有限公司 |
中樞神經系統靶向之ａａｖ衣殼之重定向
|
|
WO2025102034A1
(en)
|
2023-11-10 |
2025-05-15 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for barth syndrome
|
|
WO2025106374A1
(en)
|
2023-11-13 |
2025-05-22 |
Juno Therapeutics, Inc. |
Aav production method
|
|
WO2025106661A1
(en)
|
2023-11-14 |
2025-05-22 |
The Trustees Of The University Of Pennsylvania |
Compositions with cardiac and skeletal musclespecific targeting motifs and uses thereof
|
|
WO2025108407A2
(en)
|
2023-11-23 |
2025-05-30 |
Neuexcell Therapeutics (Suzhou) Co., Ltd. |
Gene therapy compositions and methods for treating glioma
|
|
WO2025113676A1
(en)
|
2023-11-29 |
2025-06-05 |
Neuexcell Therapeutics (Suzhou) Co., Ltd. |
Compositions and methods for treating stroke in primates
|
|
WO2025122543A1
(en)
|
2023-12-05 |
2025-06-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to syntaxin-binding protein 1 deficiency
|
|
WO2025122548A1
(en)
|
2023-12-05 |
2025-06-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to cdkl5 deficiency
|
|
WO2025122532A1
(en)
|
2023-12-05 |
2025-06-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to ataxin-2
|
|
WO2025122536A1
(en)
|
2023-12-05 |
2025-06-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to dystrophia myotonica protein kinase
|
|
WO2025129157A1
(en)
|
2023-12-15 |
2025-06-19 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treatment of canavan disease
|
|
WO2025137219A1
(en)
|
2023-12-21 |
2025-06-26 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to dystrophia myotonica protein kinase
|
|
WO2025147436A1
(en)
|
2024-01-03 |
2025-07-10 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
WO2025171001A1
(en)
|
2024-02-06 |
2025-08-14 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for improved production of aav viral vectors
|
|
TW202548022A
(zh)
|
2024-03-03 |
2025-12-16 |
美商帕西奇生物公司 |
用於治療神經退化性病症之重組腺相關病毒
|
|
US20250276095A1
(en)
|
2024-03-04 |
2025-09-04 |
Kate Therapeutics, Inc. |
Adeno-associated virus compositions for the treatment of duchenne muscular dystrophy
|
|
TW202548010A
(zh)
|
2024-03-27 |
2025-12-16 |
美商渤健麻塞諸塞州股份有限公司 |
用於靶向人類運鐵蛋白受體之ａａｖ衣殼
|
|
TW202603174A
(zh)
|
2024-03-27 |
2026-01-16 |
美商渤健麻塞諸塞州股份有限公司 |
包含抗運鐵蛋白抗體結構域之ａａｖ衣殼
|
|
TW202548025A
(zh)
|
2024-04-08 |
2025-12-16 |
美商銳進科斯生物股份有限公司 |
載體化抗補體抗體與補體劑及其投與
|
|
WO2025217214A2
(en)
|
2024-04-08 |
2025-10-16 |
Regenxbio Inc. |
Recombinant adeno-associated viruses and uses thereof
|
|
WO2025226841A1
(en)
|
2024-04-24 |
2025-10-30 |
Kate Therapeutics, Inc. |
Gene therapy approach for treating disorders associated with tnnt2
|
|
WO2025226842A1
(en)
|
2024-04-24 |
2025-10-30 |
Kate Therapeutics, Inc. |
Expression control by drg-expressed mirnas
|
|
WO2025235734A2
(en)
|
2024-05-09 |
2025-11-13 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
WO2025237990A1
(en)
|
2024-05-14 |
2025-11-20 |
Institut National de la Santé et de la Recherche Médicale |
Antisense oligonucleotides and their use for the treatment of pulmonary fibrosis
|
|
GB202407038D0
(en)
|
2024-05-17 |
2024-07-03 |
Axovia Therapeutics Ltd |
Novel Gene Therapy
|
|
WO2025242657A1
(en)
|
2024-05-21 |
2025-11-27 |
Shape Biopharmaceuticals Ag |
Lipopeptide building blocks and aggregates
|
|
WO2025250454A1
(en)
|
2024-05-28 |
2025-12-04 |
University Of Rochester |
Adeno-associated viruses evolved to specifically target human glial progenitor cells in vivo
|
|
WO2026006341A1
(en)
|
2024-06-24 |
2026-01-02 |
Regenxbio Inc. |
Microdystrophin gene therapy administration for treatment of dystrophinopathies
|
|
WO2026010829A1
(en)
*
|
2024-07-01 |
2026-01-08 |
University Of Massachusetts |
New aav capsids with enhanced muscle and peripheral nerve gene transfer efficiency
|
|
WO2026011008A1
(en)
|
2024-07-02 |
2026-01-08 |
Kate Therapeutics, Inc. |
Expression control by skeletal muscle-expressed mirnas
|
|
WO2026011009A1
(en)
|
2024-07-02 |
2026-01-08 |
Kate Therapeutics, Inc. |
Compositions and methods for muscle disorders
|
|
WO2026017965A1
(en)
|
2024-07-19 |
2026-01-22 |
The University Court Of The University Of Edinburgh |
Recombinant therapeutic fxn constructs and methods of treating friedreich ataxia and related conditions
|
|
WO2026030242A1
(en)
|
2024-07-29 |
2026-02-05 |
Kate Therapeutics, Inc. |
Adeno-associated virus compositions for the treatment of facioscapulohumeral muscular dystrophy
|
|
WO2026030244A1
(en)
|
2024-07-30 |
2026-02-05 |
Kate Therapeutics, Inc. |
Adeno-associated virus compositions for the treatment of limb girdle muscular dystrophy 2a
|
|
WO2026035687A1
(en)
|
2024-08-05 |
2026-02-12 |
University Of Rochester |
Compositions and methods for stitchr-mediated full-length scn5a expression in vivo
|
|
WO2026044005A1
(en)
|
2024-08-21 |
2026-02-26 |
Biogen Ma Inc. |
Aav particles comprising rgd-containing peptides for delivering dystrophin payloads
|
|
WO2026050402A1
(en)
|
2024-08-29 |
2026-03-05 |
Kate Therapeutics, Inc. |
Liver de-targeted muscle tropic capsids
|